Crystalline forms of thienoimidazole compounds and their preparation methods
Pharmaceutically acceptable salts of thienoimidazole compounds, particularly trometamol salt, provide stable crystalline forms with enhanced GLP-1 receptor agonist activity, addressing safety concerns of existing diabetes treatments and offering effective blood sugar control without side effects.
Patent Information
- Application Number
- JP2024533128
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-03
- Filing Date
- 2022-12-02
- Publication Date
- 2024-11-19
AI Technical Summary
Current diabetes treatments, such as insulin, sulfonylureas, metformin, and GLP-1 receptor agonists, pose safety concerns and do not effectively address long-term metabolic issues, necessitating the development of safer and more effective hypoglycemic drugs.
Development of pharmaceutically acceptable salts of thienoimidazole compounds, specifically trometamol salt, phosphate, citrate, oxalate, maleate, L-tartrate, p-toluenesulfonic acid N, sodium salt, L-arginine salt, and meglumine salt, which act as GLP-1 receptor agonists, providing stable crystalline forms A to V with unique X-ray powder diffraction patterns and thermal stability.
The thienoimidazole compounds exhibit superior GLP-1 receptor agonist activity, offering potential for safer and more effective blood sugar control without weight gain, hypoglycemia, or other side effects, and are suitable for oral administration.
Smart Images

Figure 2024543227000001_ABST
Abstract
Description
[Technical field]
[0001] The present application relates to crystalline forms of thienoimidazole-based compounds and methods for their preparation, as well as the use of said crystalline forms in the preparation of medicaments for treating related diseases. [Background technology]
[0002] Diabetes mellitus is a common metabolic disease with hyperglycemia as a common feature. Several major types of diabetes are caused by a complex interaction between genetic and environmental factors. Factors that cause hyperglycemia include impaired insulin secretion, impaired glucose utilization, and increased glucose production, and the predominance of these factors varies depending on the etiology of diabetes. Metabolic abnormalities associated with diabetes cause secondary pathophysiological changes in multiple systems throughout the body. Prolonged abnormal blood glucose levels can lead to severe complications, including cardiovascular disease, chronic renal failure, retinal damage, nerve damage, microvascular damage, obesity, and more. The classification of diabetes is based on the different pathological processes that cause hyperglycemia. Diabetes can be divided into two main types: type 1 diabetes and type 2 diabetes. In type 1 and type 2 diabetes, there is a stage of abnormal glucose homeostasis before the onset of the disease during the course of the disease. Type 1 diabetes is caused by complete or near-complete insulin deficiency. Type 2 diabetes is a heterogeneous group of diseases characterized by various degrees of insulin resistance, impaired insulin secretion, and increased glucose production. In the treatment of diabetes, the first choice for glycemic control in the early stages is dietary management and exercise therapy. If glycemic control is difficult with these methods, insulin or oral hypoglycemic drugs must be used. Currently, drugs used to treat diabetes include insulin, insulin secretagogues, metformin, insulin sensitizers, α-glucosidase inhibitors, dipeptidyl peptidase-IV inhibitors (gliptins), sodium-glucose cotransporter 2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Although these drugs have excellent therapeutic effects, there are still safety issues in long-term treatment. For example, biguanides are prone to lactic acidosis, sulfonylureas can cause hypoglycemic symptoms, insulin sensitizers can cause edema, heart failure, and weight gain, α-glucosidase inhibitors can cause abdominal pain, abdominal distension, diarrhea, and other symptoms, and sodium-glucose cotransporter 2 (SGLT2) inhibitors increase the risk of urinary tract and reproductive tract infections.Therefore, there is an urgent need to develop new, safer and more effective hypoglycemic drugs to meet the therapeutic needs of diabetes.
[0003] Glucagon-like peptide-1 receptor (GLP-1R) is one of the most important therapeutic targets for type 2 diabetes. GLP-1R is a member of the G protein-coupled receptor B cluster subfamily and is widely expressed in tissues such as the stomach, small intestine, heart, kidney, lung, and brain in vivo. In pancreatic islet cells, GLP-1R mainly promotes insulin release, increases islet B cell renewal, inhibits B cell apoptosis, and decreases glucagon release. In tissues such as the gastrointestinal tract, GLP-1R can be combined with its agonists to inhibit gastrointestinal peristalsis and gastric juice secretion, delay gastric emptying, and enhance satiety. In neural tissues, small molecule GLP-1R agonists can penetrate the brain to activate a subset of GLP-1R-expressing neurons, protect neurons from apoptosis, and enhance learning and memory capabilities. In addition, GLP-1R can also control food intake to reduce weight. GLP-1 receptor agonists or endogenous GLP-1 activity enhancers are approved for the treatment of type 2 diabetes. These drugs do not cause hypoglycemia because secretin-stimulated insulin secretion is dependent on glucose. Exenatide is a type of artificially synthesized peptide, originally found in the saliva of Heloderma, and is a GLP-1 analog. Compared with natural GLP-1, exenatide has a different amino acid sequence, making it resistant to the enzyme that breaks down GLP-1 [dipeptidyl peptidase IV (DPP-IV)]. Therefore, exenatide has extended GLP-1-like activity and can bind to GLP-1 receptors in pancreatic islets, gastrointestinal tract and brain. Liraglutide, another GLP-1 receptor agonist, is almost identical to natural GLP-1, except for replacing one of the amino acids and adding one fatty acyl group. This fatty acyl group can promote binding to albumin and plasma proteins and extend the half-life. GLP-1 receptor agonists can increase glucose-stimulated insulin secretion, inhibit glucagon, and delay gastric emptying. These drugs do not cause weight gain; in fact, most patients experience some weight loss and some reduction in appetite.
[0004] DPP-IV inhibitors inhibit the degradation of natural GLP-1, thereby enhancing the effect of secretin. DPP-IV is fully expressed on the cell surface of endothelial cells and some lymphocytes, and can degrade various polypeptides (not just GLP-1). DPP-IV inhibitors have more advantages in terms of promoting insulin secretion without lowering blood glucose levels, not causing weight gain, and lowering postprandial blood glucose levels. Patients who used GLP-1 receptor agonists showed higher levels of GLP-1 activity than those who used DPP-IV inhibitors.
[0005] Developing small molecule GLP-1 receptor agonists with oral activity can effectively avoid patients' long-term self-injection and obtain good compliance. Small molecule GLP-1 receptor agonists can control blood glucose through multiple pathways, including glucose metabolism and excretion, and are therefore expected to lead to the development of new, safer and more effective hypoglycemic drugs to meet the treatment needs of diabetes. Summary of the Invention
[0006] The present invention provides pharma- ceutically acceptable salts of compounds of formula (O).
[0007] [ka] Here, the pharma- ceutically acceptable salt is selected from the group consisting of trometamol salt, phosphate salt, citrate salt, oxalate salt, maleate salt, L-tartrate salt, p-toluenesulfonic acid N, sodium salt, potassium salt, L-arginine salt, hydroxycholine salt, and meglumine salt, preferably trometamol salt, phosphate salt, oxalate salt, maleate salt, p-toluenesulfonic acid N, L-arginine salt, and meglumine salt, and more preferably trometamol salt and meglumine salt.
[0008] In some embodiments of the invention, the chemical molar ratio of the compound to the acid or base molecule is 1:2 to 2:1, and may be, for example, 2:3, 3:4, 4:5, 1:1, 5:4, 4:3, 3:2. In some embodiments, the chemical molar ratio is preferably 1:2 to 1:1. In some embodiments, the chemical molar ratio is preferably 1:1 to 2:1. In some embodiments, the chemical molar ratio is preferably 1:2, 1:1, or 2:1.
[0009] The present invention provides a process for preparing the above pharma- ceutically acceptable salts, which comprises the step of forming a salt of a compound of formula (I) with an acid or base. In some embodiments of the invention, the solvent used in the salt formation reaction is at least one selected from butanone, methanol, ethanol, tetrahydrofuran, ethyl acetate, isopropanol, acetonitrile, and methyl tert-butyl ether.
[0010] The present invention provides a pharmaceutical composition comprising the above pharma- ceutically acceptable salt and, optionally, a pharma- ceutically acceptable carrier, excipient. In some aspects of the invention there is provided the use of a pharma- ceutically acceptable salt as described above in the preparation of a medicament for the prophylaxis and / or treatment of a metabolic disease, preferably wherein said metabolic disease is diabetes, obesity, or non-alcoholic fatty liver disease.
[0011] The present invention provides a compound of formula (II):
[0012] [ka] In the formula, n is selected from 0 to 12, and may be, for example, 0, 1 / 2, 2 / 3, 1, 2, 2.7, 3, 4, 5, 6, 7, 8. In some embodiments of the invention, n is selected from 0 to 8. In some embodiments of the invention, n is selected from 0 to 5. In some embodiments of the invention, n is selected from 0 to 3.
[0013] In some embodiments of the invention, n is selected from 0, ½, ⅔, 1, 2, 2.7, and 3. In some aspects of the invention, the compound of formula (II) has the structure:
[0014] [ka]
[0015] The present invention provides crystalline form A of compound of formula (II-1), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 11.1426±0.2000°, 14.4804±0.2000°, and 21.4921±0.2000°.
[0016] [ka]
[0017] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above crystalline form A has characteristic diffraction peaks at the following 2θ angles: 11.1426±0.2000°, 14.4804±0.2000°, 17.7642±0.2000°, 19.6235±0.2000°, and 21.4921±0.2000°.
[0018] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form A has characteristic diffraction peaks at the following 2θ angles: 11.1426±0.2000°, 14.4804±0.2000°, 17.0921±0.2000°, 17.7642±0.2000°, 19.6235±0.2000°, 20.4359±0.2000°, 21.4921±0.2000°, and 22.8874±0.2000°.
[0019] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form A has characteristic diffraction peaks at the following 2θ angles: 5.6759°, 10.2572°, 11.1426°, 14.4804°, 16.2701°, 17.0921°, 17.7642°, 19.6235°, 20.4359°, 20.9310°, 21.4921°, 22.8874°, 25.1971°, 26.5995°, 27.9955°, 28.6836°, 29.4212°, and 30.9896°.
[0020] In some embodiments of the present invention, the XRPD pattern of crystalline form A above is essentially as shown in FIG. In some embodiments of the present invention, the analytical data of the XRPD pattern of crystalline form A above is shown in Table 1.
[0021] [Table 1]
[0022] In some embodiments of the present invention, the differential scanning calorimetry curve for said crystalline form A has endothermic peak values at 76.0±3.0° C. and 130.3±3.0° C., respectively.
[0023] In some embodiments of the present invention, the DSC thermogram of crystalline form A above is essentially as shown in FIG. In some embodiments of the present invention, the thermogravimetric analysis curve for crystalline form A above has a weight loss of 2.43% at 150.0±3.0° C.
[0024] In some embodiments of the present invention, the TGA spectrum of crystalline form A above is essentially as shown in FIG. The present invention provides crystalline form B of compound of formula (II), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 13.3946±0.2000°, 16.0867±0.2000°, and 18.7923±0.2000°.
[0025] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form B has characteristic diffraction peaks at the following 2θ angles: 5.3578±0.2000°, 10.7076±0.2000°, 13.3946±0.2000°, 16.0867±0.2000°, and 18.7923±0.2000°.
[0026] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form B has characteristic diffraction peaks at the following 2θ angles: 5.3578±0.2000°, 10.7076±0.2000°, 13.3946±0.2000°, 16.0867±0.2000°, 18.7923±0.2000°, and 26.9882±0.2000°.
[0027] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form B has characteristic diffraction peaks at the following 2θ angles: 5.3578°, 10.7076°, 13.3946°, 16.0867°, 17.2158°, 18.7923°, 20.0218°, 20.7079°, 21.5030°, 23.0606°, 24.3029°, 25.5466°, 26.9882°, 28.4762°, 29.7465°, 30.8461°, 32.5003°, 35.2977°, 37.0829°, and 38.1654°.
[0028] In some embodiments of the present invention, the XRPD pattern of crystalline form B above is essentially as shown in FIG. In some embodiments of the present invention, the analytical data of the XRPD pattern of crystalline form B is shown in Table 2.
[0029] [Table 2]
[0030] The present invention provides a crystalline form C of the compound of formula (II), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 5.2235±0.2000°, 13.0633±0.2000°, and 18.3202±0.2000°.
[0031] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form C has characteristic diffraction peaks at the following 2θ angles: 5.2235±0.2000°, 13.0633±0.2000°, 18.3202±0.2000°, 19.0603±0.2000°, and 20.9687±0.2000°.
[0032] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form C has characteristic diffraction peaks at the following 2θ angles: 5.2235±0.2000°, 10.6330±0.2000°, 13.0633±0.2000°, 18.3202±0.2000°, 19.0603±0.2000°, 20.9687±0.2000°, 23.0438±0.2000°, and 23.6332±0.2000°.
[0033] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form C is shown to be consistent with the following 2θ angles: 5.2235°, 10.2060°, 10.4366°, 10.6330°, 11.6394°, 13.0633°, 16.3161°, 16.8840°, 17.9453°, 18.3202°, 19.0603°, 19.6631°, 20.5231°, 20.9687°, 21.3445°, 21.97 It has characteristic diffraction peaks at 52°, 22.4037°, 23.0438°, 23.3931°, 23.6332°, 23.9781°, 24.7774°, 25.4626°, 26.2681°, 26.7514°, 28.0533°, 28.9221°, 29.4437°, 30.4397°, 30.9179°, 32.6038°, 34.3656°, 36.3357°, and 37.4691°.
[0034] In some embodiments of the present invention, the XRPD pattern of crystalline form C above is essentially as shown in FIG. In some embodiments of the present invention, the analytical data for the XRPD pattern of crystalline form C is shown in Table 3.
[0035] [Table 3]
[0036] The present invention provides a crystalline form D of compound of formula (II), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 5.4120±0.2000°, 13.5502±0.2000°, and 24.5140±0.2000°.
[0037] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form D has characteristic diffraction peaks at the following 2θ angles: 5.4120±0.2000°, 8.1209±0.2000°, 13.5502±0.2000°, 16.2767±0.2000°, and 24.5140±0.2000°.
[0038] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form D has characteristic diffraction peaks at the following 2θ angles: 5.4120±0.2000°, 8.1209±0.2000°, 13.5502±0.2000°, 16.2767±0.2000°, 18.9363±0.2000°, 20.4857±0.2000°, 21.7578±0.2000°, and 24.5140±0.2000°.
[0039] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form D is shown to be consistent with the following 2θ angles: 5.4120°, 8.1209°, 10.4811°, 10.8250°, 11.4035°, 12.8266°, 13.5502°, 14.6390°, 16.2767°, 17.3099°, 17.6879°, 18.9363°, 20.4857°, 21.0182°, 22.0181°, 23.0182°, 24.0181°, 25.0182°, 26.0182°, 27.0182°, 28.0182°, 29.0182°, 30.0182°, 31.0182°, 32.0182°, 33.0182°, 34.0182°, 35.0182°, 36.0182°, 37.0182°, 38.0182°, 39.0182°, 40.0182°, 41.0182°, 42.0182°, 43.0182°, 44.0182°, 45.0182°, 46.0182°, 47.0182°, 48.0182°, 49.0182°, 50.0182°, 51.0182°, 52.0182°, 53.0182°, 54.0182°, 55.0182°, It has characteristic diffraction peaks at 0.9317°, 21.4104°, 21.7578°, 21.9895°, 22.3592°, 22.9155°, 23.6785°, 24.5140°, 25.0791°, 25.8055°, 26.2813°, 27.7237°, 29.5078°, 30.9747°, 36.0140°, and 36.8748°.
[0040] In some embodiments of the present invention, the XRPD pattern of crystalline form D above is essentially as shown in FIG. In some embodiments of the present invention, the analytical data for the XRPD pattern of crystalline form D above is shown in Table 4.
[0041] [Table 4]
[0042] The present invention provides a crystalline form E of compound of formula (II), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 18.8216±0.2000°, 20.0568±0.2000°, and 25.1936±0.2000°.
[0043] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above crystalline form E has characteristic diffraction peaks at the following 2θ angles: 10.8415±0.2000°, 13.3963±0.2000°, 18.8216±0.2000°, 20.0568±0.2000°, and 25.1936±0.2000°.
[0044] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form E has characteristic diffraction peaks at the following 2θ angles: 10.3742±0.2000°, 10.8415±0.2000°, 13.3963±0.2000°, 16.1259±0.2000°, 18.8216±0.2000°, 20.0568±0.2000°, 20.7958±0.2000°, and 25.1936±0.2000°.
[0045] The present invention relates to an X-ray powder diffraction pattern having a diffraction pattern at the following 2θ angles: 18.8216±0.2000°, 20.0568±0.2000°, and / or 25.1936±0.2000°, and / or 10.8415±0.2000°, and / or 13.3963±0.2000°, and / or 10.3742±0.2000°, and / or 16.1259±0.2000°, and / or 20.795 8±0.2000°, and / or 5.3759±0.2000°, and / or 11.5008±0.2000°, and / or 15.7418±0.2000°, and / or 16.6392±0.2000°, and / or 17.2881±0.2000°, and / or 19.2577±0.2000°, and / or 21.4850±0.2000°, and / or 22.1639±0 .2000°, and / or 23.0777±0.2000°, and / or 24.1467±0.2000°, and / or 24.6828±0.2000°, and / or 25.5960±0.2000°, and / or 26.2392±0.2000°, and / or 26.7365±0.2000°, and / or 27.1146±0.2000°, and / or 27.8176±0.2 The present invention provides a crystalline form E of compound of formula (II), characterised by having characteristic diffraction peaks at 28.000°, and / or 28.5679±0.2000°, and / or 29.6443±0.2000°, and / or 30.8753±0.2000°, and / or 33.0123±0.2000°, and / or 33.8173±0.2000°, and / or 36.5754±0.2000°.
[0046] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above crystalline form E is obtained from the following 2θ angles: 5.3759°, 10.3742°, 10.8415°, 11.5008°, 13.3963°, 15.7418°, 16.1259°, 16.6392°, 17.2881°, 18.8216°, 19.2577°, 20.0568°, 20.7958°, 21.48 It has characteristic diffraction peaks at 50°, 22.1639°, 23.0777°, 24.1467°, 24.6828°, 25.1936°, 25.5960°, 26.2392°, 26.7365°, 27.1146°, 27.8176°, 28.5679°, 29.6443°, 30.8753°, 33.0123°, 33.8173°, and 36.5754°.
[0047] In some embodiments of the present invention, the XRPD pattern of crystalline form E above is essentially as shown in FIG. In some embodiments of the present invention, the analytical data for the XRPD pattern of crystalline form E above is shown in Table 5.
[0048] [Table 5]
[0049] In some embodiments of the present invention, the differential scanning calorimetry curve for crystalline form E above has endothermic peak values at 91.0±3.0° C. and 149.9±3.0° C., respectively.
[0050] In some embodiments of the present invention, the DSC thermogram of crystalline form E above is essentially as shown in FIG. In some embodiments of the present invention, the thermogravimetric analysis curve for crystalline form E above has a weight loss of 6.37% at 150.0±3.0° C.
[0051] In some embodiments of the present invention, the TGA spectrum of crystalline form E above is essentially as shown in FIG. The present invention provides a crystalline form F of the compound of formula (II), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 5.4518±0.2000°, 19.3372±0.2000°, and 20.6984±0.2000°.
[0052] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form F has characteristic diffraction peaks at the following 2θ angles: 5.4518±0.2000°, 10.5789±0.2000°, 16.4789±0.2000°, 19.3372±0.2000°, and 20.6984±0.2000°.
[0053] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form F has characteristic diffraction peaks at the following 2θ angles: 5.4518±0.2000°, 10.5789±0.2000°, 16.4789±0.2000°, 17.7935±0.2000°, 19.3372±0.2000°, 20.6984±0.2000°, 22.3282±0.2000°, and 26.3477±0.2000°.
[0054] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form F has characteristic diffraction peaks at the following 2θ angles: 5.4518°, 10.5789°, 11.5837°, 13.0825°, 14.9423°, 16.4789°, 17.7935°, 19.3372°, 20.6984°, 21.2538°, 22.3282°, 24.7246°, 26.3477°, 27.4475°, and 28.7110°.
[0055] In some embodiments of the present invention, the XRPD pattern of crystalline form F above is essentially as shown in FIG. In some embodiments of the present invention, analytical data for the XRPD pattern of crystalline form F above is shown in Table 6.
[0056] [Table 6]
[0057] The present invention provides a crystalline form G of the compound of formula (II), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 13.2453±0.2000°, 18.1001±0.2000°, and 20.5915±0.2000°.
[0058] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form G has characteristic diffraction peaks at the following 2θ angles: 5.3356±0.2000°, 13.2453±0.2000°, 18.1001±0.2000°, 19.3293±0.2000°, and 20.5915±0.2000°.
[0059] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form G has characteristic diffraction peaks at the following 2θ angles: 5.3356±0.2000°, 13.2453±0.2000°, 18.1001±0.2000°, 18.5528±0.2000°, 19.3293±0.2000°, 19.7622±0.2000°, 20.5915±0.2000°, and 23.5540±0.2000°.
[0060] In some embodiments of the present invention, the X-ray powder diffraction pattern of the crystalline form G has characteristic diffraction peaks at the following 2θ angles: 5.3356°, 10.7072°, 13.2453°, 14.9037°, 16.6883°, 18.1001°, 18.5528°, 19.3293°, 19.7622°, 20.5915°, 21.3864°, 22.0249°, 22.5324°, 23.1856°, 23.5540°, 24.9841°, 25.5102°, 26.9502°, 28.1389°, 29.0651°, and 30.3926°.
[0061] In some embodiments of the present invention, the XRPD pattern of crystalline form G above is essentially as shown in FIG. In some embodiments of the present invention, analytical data for the XRPD pattern of crystalline form G above is shown in Table 7.
[0062] [Table 7]
[0063] The present invention provides a crystalline form H of compound of formula (II), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 5.2142±0.2000°, 9.2475±0.2000°, and 17.8933±0.2000°.
[0064] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form H has characteristic diffraction peaks at the following 2θ angles: 5.2142±0.2000°, 9.2475±0.2000°, 17.8933±0.2000°, 22.0544±0.2000°, and 23.0224±0.2000°.
[0065] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form H has characteristic diffraction peaks at the following 2θ angles: 5.2142±0.2000°, 9.2475±0.2000°, 17.8933±0.2000°, 19.3686±0.2000°, 20.2031±0.2000°, 21.2391±0.2000°, 22.0544±0.2000°, and 23.0224±0.2000°.
[0066] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form H has characteristic diffraction peaks at the following 2θ angles: 5.2142°, 9.2475°, 10.2712°, 13.6133°, 15.5872°, 16.1306°, 17.8933°, 18.7847°, 19.3686°, 20.2031°, 20.7049°, 21.2391°, 22.0544°, 23.0224°, 24.1930°, and 26.9749°.
[0067] In some embodiments of the present invention, the XRPD pattern of crystalline form H above is essentially as shown in FIG. In some embodiments of the present invention, analytical data for the XRPD pattern of crystalline form H above is shown in Table 8.
[0068] [Table 8]
[0069] The present invention provides crystalline form I of compound of formula (II), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 5.1906±0.2000°, 12.9022±0.2000°, and 15.4944±0.2000°.
[0070] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline Form I has characteristic diffraction peaks at the following 2θ angles: 5.1906±0.2000°, 10.3443±0.2000°, 12.9022±0.2000°, 15.4944±0.2000°, and 18.0816±0.2000°.
[0071] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline Form I has characteristic diffraction peaks at the following 2θ angles: 5.1906±0.2000°, 10.3443±0.2000°, 12.9022±0.2000°, 13.4027±0.2000°, 15.4944±0.2000°, 16.1068±0.2000°, 18.0816±0.2000°, and 18.8121±0.2000°.
[0072] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline Form I has characteristic diffraction peaks at the following 2θ angles: 5.1906°, 7.7331°, 10.3443°, 10.7143°, 12.9022°, 13.4027°, 15.4944°, 16.1068°, 18.0816°, 18.8121°, 23.3219°, 26.9651°, and 28.5725°.
[0073] In some embodiments of the present invention, the XRPD pattern of crystalline Form I above is essentially as shown in FIG. In some embodiments of the present invention, analytical data for the XRPD pattern of crystalline Form I above is shown in Table 9.
[0074] [Table 9]
[0075] The present invention also relates to a compound of formula (III)
[0076] [ka] wherein i is selected from 0 to 2, and may be, for example, 0, ½, ⅔, 1, 1.5, 2.
[0077] The present invention provides a crystalline form J of the compound of formula (III), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 6.763±0.200°, 13.619±0.200°, and 18.128±0.200°.
[0078] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above crystalline form J has characteristic diffraction peaks at the following 2θ angles: 6.763±0.200°, 13.619±0.200°, 15.848±0.200°, 18.128±0.200°, and 24.643±0.200°.
[0079] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above crystalline form J has characteristic diffraction peaks at the following 2θ angles: 6.763±0.200°, 13.619±0.200°, 15.848±0.200°, 18.128±0.200°, 19.438±0.200°, 21.422±0.200°, 22.621±0.200°, and 24.643±0.200°.
[0080] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above crystalline form J is obtained from the following 2θ angles: 6.763°, 9.065°, 9.535°, 11.902°, 12.066°, 12.874°, 13.619°, 14.169°, 14.918°, 15.848°, 16.105°, 16.573°, 17.620°, 18.128°, 18.510°, 18.826°, 19.107°, 19.438°, 20.5 It has characteristic diffraction peaks at 38°, 21.191°, 21.422°, 21.794°, 22.416°, 22.621°, 22.806°, 23.376°, 23.609°, 24.643°, 25.149°, 25.650°, 27.329°, 28.990°, 29.368°, 29.916°, 30.162°, 31.416°, 33.040°, 33.684°, 35.327°, and 37.570°.
[0081] In some embodiments of the present invention, the XRPD pattern of crystalline form J above is essentially as shown in FIG. In some embodiments of the present invention, analytical data for the XRPD pattern of crystalline form J above is shown in Table 10.
[0082] [Table 10] TIFF2024543227000017.tif187170
[0083] The present invention also relates to a compound of formula (IV)
[0084] [ka] wherein m is selected from 0 to 2, and may be, for example, 0, ½, ⅔, 1, 1.5, 2.
[0085] In some forms of the invention, the compound of formula (IV) has the structure:
[0086] [ka]
[0087] The present invention provides a crystalline form K of the compound of formula (IV-I), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 16.860±0.200°, 18.189±0.200°, and 20.709±0.200°.
[0088] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above crystalline form K has characteristic diffraction peaks at the following 2θ angles: 9.972±0.200°, 16.860±0.200°, 18.189±0.200°, 20.709±0.200°, and 23.950±0.200°.
[0089] In some embodiments of the present invention, the X-ray powder diffraction pattern of the crystalline form K has characteristic diffraction peaks at the following 2θ angles: 4.581±0.200°, 9.972±0.200°, 10.392±0.200°, 16.860±0.200°, 18.189±0.200°, 20.709±0.200°, 23.950±0.200°, and 26.841±0.200°.
[0090] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above crystalline form K has characteristic diffraction peaks at the following 2θ angles: 4.581°, 6.439°, 9.972°, 10.232°, 10.392°, 13.328°, 14.053°, 14.696°, 16.860°, 18.189°, 20.709°, 22.766°, 23.950°, 25.785°, and 26.841°.
[0091] In some embodiments of the present invention, the XRPD pattern of crystalline form K above is essentially as shown in FIG. In some embodiments of the present invention, the analytical data for the XRPD pattern of crystalline form K is shown in Table 11.
[0092] [Table 11]
[0093] The present invention provides a crystalline form L of the compound of formula (IV), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 18.726±0.200°, 21.044±0.200°, and 24.648±0.200°.
[0094] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form L has characteristic diffraction peaks at the following 2θ angles: 6.494±0.200°, 18.726±0.200°, 19.547±0.200°, 21.044±0.200°, and 24.648±0.200°.
[0095] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form L has characteristic diffraction peaks at the following 2θ angles: 6.494±0.200°, 15.366±0.200°, 17.885±0.200°, 18.726±0.200°, 19.547±0.200°, 21.044±0.200°, 24.648±0.200°, and 27.453±0.200°.
[0096] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form L has characteristic diffraction peaks at the following 2θ angles: 5.797°, 6.494°, 7.655°, 10.474°, 13.036°, 13.388°, 15.366°, 16.235°, 17.885°, 18.726°, 19.547°, 21.044°, 24.368°, 24.648°, and 27.453°.
[0097] In some embodiments of the present invention, the XRPD pattern of crystalline form L above is essentially as shown in FIG. In some embodiments of the present invention, analytical data for the XRPD pattern of crystalline form L above is shown in Table 12.
[0098] [Table 12]
[0099] The present invention also relates to a compound of formula (V)
[0100] [ka] wherein o is selected from 0 to 2, and may be, for example, 0, ½, ⅔, 1, 1.5, 2.
[0101] The present invention provides a crystalline form M of compound of formula (V), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 5.682±0.200°, 11.389±0.200°, and 17.202±0.200°.
[0102] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form M has characteristic diffraction peaks at the following 2θ angles: 5.682±0.200°, 11.389±0.200°, 16.009±0.200°, 17.202±0.200°, and 29.418±0.200°.
[0103] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form M has characteristic diffraction peaks at the following 2θ angles: 5.682±0.200°, 11.389±0.200°, 16.009±0.200°, 17.202±0.200°, 17.854±0.200°, 24.147±0.200°, 25.302±0.200°, and 29.418±0.200°.
[0104] In some embodiments of the invention, the X-ray powder diffraction pattern of crystalline form M has characteristic diffraction peaks at the following 2θ angles: 5.682°, 10.619°, 11.389°, 12.280°, 12.637°, 14.434°, 15.764°, 16.009°, 17.202°, 17.854°, 18.783°, 19.352°, 20.673°, 21.044°, 21.729°, 22.632°, 23.341°, 24.147°, 25.302°, 26.982°, 28.950°, 29.418°, 30.123°, and 33.086°.
[0105] In some embodiments of the present invention, the XRPD pattern of crystalline form M above is essentially as shown in FIG. In some embodiments of the present invention, analytical data for the XRPD pattern of crystalline form M above is shown in Table 13.
[0106] [Table 13] TIFF2024543227000024.tif51170
[0107] The present invention also provides a compound of formula (VI).
[0108] [ka]
[0109] The present invention provides a crystalline form N of the compound of formula (VI), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 11.439±0.200°, 18.363±0.200°, and 28.859±0.200°.
[0110] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above crystalline form N has characteristic diffraction peaks at the following 2θ angles: 11.439±0.200°, 18.363±0.200°, 20.062±0.200°, 22.657±0.200°, and 28.859±0.200°.
[0111] In some embodiments of the invention, the X-ray powder diffraction pattern of crystalline form N has characteristic diffraction peaks at the following 2θ angles: 8.581±0.200°, 11.439±0.200°, 18.363±0.200°, 20.062±0.200°, 22.657±0.200°, 23.664±0.200°, 25.356±0.200°, and 28.859±0.200°.
[0112] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above crystalline form N is obtained from the following 2θ angles: 5.697°, 8.581°, 8.801°, 11.439°, 12.051°, 12.568°, 13.226°, 14.357°, 14.846°, 15.655°, 16.120°, 17.223°, 17.880°, 18.363°, 18.914°, 19.236°, 20.062°, 20.397°, It has characteristic diffraction peaks at 21.454°, 22.657°, 22.991°, 23.664°, 24.391°, 24.844°, 25.356°, 26.003°, 26.573°, 26.956°, 27.309°, 28.283°, 28.859°, 29.089°, 29.935°, 31.553°, 31.847°, 32.174°, 32.715°, 34.782°, and 38.569°.
[0113] In some embodiments of the present invention, the XRPD pattern of crystalline form N above is essentially as shown in FIG. In some embodiments of the present invention, the analytical data for the XRPD pattern of crystalline form N is shown in Table 14.
[0114] [Table 14] TIFF2024543227000027.tif188170
[0115] The present invention also relates to a compound of formula (VII)
[0116] [ka] wherein p is selected from 0 to 3, and may be, for example, 0, ½, ⅔, 1, 1.5, 2, 2.5, 2.7, 3.
[0117] The present invention provides crystalline form O of compound of formula (VII), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.485±0.200°, 11.273±0.200°, and 17.536±0.200°.
[0118] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form O has characteristic diffraction peaks at the following 2θ angles: 9.485±0.200°, 11.273±0.200°, 12.495±0.200°, 17.536±0.200°, and 18.874±0.200°.
[0119] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form O has characteristic diffraction peaks at the following 2θ angles: 9.485±0.200°, 11.273±0.200°, 12.495±0.200°, 15.005±0.200°, 17.536±0.200°, 18.874±0.200°, 19.568±0.200°, and 20.291±0.200°.
[0120] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form O has characteristic diffraction peaks at the following 2θ angles: 4.859°, 7.487°, 9.485°, 10.000°, 11.273°, 12.495°, 12.842°, 14.649°, 15.005°, 16.766°, 17.536°, 18.874°, 19.568°, 20.082°, 20.291°, 21.189°, 22.679°, 23.508°, 25.140°, 25.788°, 28.081°, 29.067°, 29.739°, 31.639°, and 35.581°.
[0121] In some embodiments of the present invention, the XRPD pattern of crystalline form O above is essentially as shown in FIG. In some embodiments of the present invention, the analytical data for the XRPD pattern of crystalline form O above is shown in Table 15.
[0122] [Table 15] TIFF2024543227000030.tif61170
[0123] The present invention provides a crystalline form P of compound of formula (VII), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 12.481±0.200°, 14.965±0.200°, and 17.480±0.200°.
[0124] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form P has characteristic diffraction peaks at the following 2θ angles: 9.998±0.200°, 12.481±0.200°, 14.965±0.200°, 17.480±0.200°, and 19.969±0.200°.
[0125] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form P has characteristic diffraction peaks at the following 2θ angles: 5.007°, 7.512°, 9.604°, 9.998°, 12.481°, 14.965°, 17.480°, 18.908°, 19.969°, 20.933°, 25.629°, 27.587°, and 35.375°.
[0126] In some embodiments of the present invention, the XRPD pattern of crystalline form P above is essentially as shown in FIG. In some embodiments of the present invention, the analytical data for the XRPD pattern of crystalline form P is shown in Table 16.
[0127] [Table 16]
[0128] The present invention also provides a compound of formula (VIII).
[0129] [ka]
[0130] The present invention provides a crystalline form Q of the compound of formula (VIII), having an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 6.123±0.200°, 9.130±0.200°, and 12.123±0.200°.
[0131] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above crystalline form Q has characteristic diffraction peaks at the following 2θ angles: 6.123±0.200°, 9.130±0.200°, 12.123±0.200°, 20.095±0.200°, and 22.942±0.200°.
[0132] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above crystalline form Q has characteristic diffraction peaks at the following 2θ angles: 6.123±0.200°, 9.130±0.200°, 12.123±0.200°, 15.071±0.200°, 18.151±0.200°, 20.095±0.200°, 22.045±0.200°, and 22.942±0.200°.
[0133] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above crystalline form Q is obtained from the following 2θ angles: 6.123°, 7.677°, 9.130°, 10.013°, 11.598°, 12.123°, 14.770°, 15.071°, 15.986°, 16.493°, 16.692°, 17.365°, 18.151°, 18.915°, 20.095°, 20.5 It has characteristic diffraction peaks at 69°, 21.147°, 22.045°, 22.942°, 24.106°, 24.617°, 26.108°, 27.014°, 27.822°, 28.433°, 29.464°, 30.256°, 30.863°, 31.820°, 33.446°, 34.822°, 36.389°, 37.646°, and 37.803°.
[0134] In some embodiments of the present invention, the XRPD pattern of crystalline form Q above is essentially as shown in FIG. In some embodiments of the present invention, the analytical data for the XRPD pattern of crystalline form Q above is shown in Table 17.
[0135] [Table 17] TIFF2024543227000034.tif143170
[0136] The present invention also relates to a compound of formula (I)
[0137] [ka] wherein s is selected from 0 to 3, and may be, for example, 0, ½, ⅔, 1, 1.5, 2, 2.5, 2.7, 3.
[0138] In some embodiments of the invention, s is selected from 0, 1, 2, and 3. In some forms of the invention, the compound of formula (I) has the structure:
[0139] [ka]
[0140] The present invention provides a crystalline form R of compound of formula (I), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 7.933±0.200°, 15.900±0.200°, and 23.970±0.200°.
[0141] In some embodiments of the present invention, the X-ray powder diffraction pattern of the above crystalline form R has characteristic diffraction peaks at the following 2θ angles: 7.933±0.200°, 11.906±0.200°, 15.900±0.200°, 19.923±0.200°, and 23.970±0.200°.
[0142] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form R has characteristic diffraction peaks at the following 2θ angles: 3.935±0.200°, 7.933±0.200°, 11.906±0.200°, 15.900±0.200°, 19.923±0.200°, and 23.970±0.200°.
[0143] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form R has characteristic diffraction peaks at the following 2θ angles: 3.935°, 7.933°, 11.906°, 15.900°, 17.731°, 19.923°, 21.294°, 23.503°, 23.970°, 25.040°, 26.811°, 28.041°, 28.913°, 31.180°, 32.172°, 34.091°, and 38.072°.
[0144] In some embodiments of the present invention, the XRPD pattern of crystalline form R above is essentially as shown in FIG. In some embodiments of the present invention, the analytical data for the XRPD pattern of crystalline form R is shown in Table 18.
[0145] [Table 18]
[0146] The present invention provides a crystalline form S of compound of formula (I), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 20.032±0.200°, 21.239±0.200°, and 23.474±0.200°.
[0147] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form S has characteristic diffraction peaks at the following 2θ angles: 15.569±0.200°, 17.781±0.200°, 20.032±0.200°, 21.239±0.200°, and 23.474±0.200°.
[0148] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form S has characteristic diffraction peaks at the following 2θ angles: 14.527±0.200°, 15.569±0.200°, 17.781±0.200°, 20.032±0.200°, 21.239±0.200°, 23.474±0.200°, 24.275±0.200°, and 26.863±0.200°.
[0149] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form S has characteristic diffraction peaks at the following 2θ angles: 3.871°, 7.901°, 9.387°, 9.859°, 11.461°, 14.527°, 15.569°, 15.906°, 16.743°, 17.781°, 18.461°, 20.032°, 20.378°, 21.239°, 23.474°, 24.275°, 25.367°, 26.863°, 27.063°, 28.954°, 31.135°, and 34.181°.
[0150] In some embodiments of the present invention, the XRPD pattern of crystalline form S above is essentially as shown in FIG. In some embodiments of the present invention, analytical data for the XRPD pattern of crystalline form S above is shown in Table 19.
[0151] [Table 19] TIFF2024543227000039.tif32170
[0152] The present invention provides a crystalline form T of the compound of formula (I-1), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 6.347±0.200°, 11.735±0.200°, and 18.221±0.200°.
[0153] In some embodiments of the present invention, the X-ray powder diffraction pattern of the crystalline form T has characteristic diffraction peaks at the following 2θ angles: 6.347±0.200°, 11.012±0.200°, 11.735±0.200°, 18.221±0.200°, and 20.525±0.200°.
[0154] In some embodiments of the present invention, the X-ray powder diffraction pattern of the crystalline form T has characteristic diffraction peaks at the following 2θ angles: 6.347±0.200°, 11.012±0.200°, 11.735±0.200°, 15.525±0.200°, 17.028±0.200°, 18.221±0.200°, 20.525±0.200°, and 25.872±0.200°.
[0155] In some embodiments of the present invention, the X-ray powder diffraction pattern of the crystalline form T has characteristic diffraction peaks at the following 2θ angles: 6.347°, 9.315°, 10.351°, 11.012°, 11.735°, 12.780°, 14.017°, 15.525°, 16.475°, 17.028°, 18.221°, 19.285°, 20.213°, 20.525°, 22.738°, 23.383°, 23.924°, 25.039°, 25.872°, 26.855°, and 31.419°.
[0156] In some embodiments of the present invention, the XRPD pattern of crystalline form T above is essentially as shown in FIG. In some embodiments of the present invention, the analytical data for the XRPD pattern of crystalline form T is shown in Table 20.
[0157] [Table 20] TIFF2024543227000041.tif22170
[0158] The present invention provides a crystalline form U of compound of formula (I-1), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 4.486±0.200°, 9.021±0.200°, and 27.215±0.200°.
[0159] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form U has characteristic diffraction peaks at the following 2θ angles: 4.486±0.200°, 9.021±0.200°, 14.894±0.200°, 23.876±0.200°, and 27.215±0.200°.
[0160] In some embodiments of the invention, the X-ray powder diffraction pattern of crystalline form U has characteristic diffraction peaks at the following 2θ angles: 4.486±0.200°, 9.021±0.200°, 14.894±0.200°, 18.620±0.200°, 19.150±0.200°, 22.042±0.200°, 23.876±0.200°, and 27.215±0.200°.
[0161] In some embodiments of the invention, the X-ray powder diffraction pattern of crystalline form U has characteristic diffraction peaks at the following 2θ angles: 4.486°, 9.021°, 10.970°, 13.600°, 14.894°, 15.853°, 18.076°, 18.620°, 19.150°, 22.042°, 23.876°, 26.295°, 27.215°, 28.304°, 30.674°, and 31.304°.
[0162] In some embodiments of the present invention, the XRPD pattern of crystalline form U above is essentially as shown in FIG. In some embodiments of the present invention, the analytical data for the XRPD pattern of crystalline form U above is shown in Table 21.
[0163] [Table 21]
[0164] The present invention provides crystalline form V of compound of formula (I), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 3.729±0.200°, 11.208±0.200°, and 23.480±0.200°.
[0165] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form V has characteristic diffraction peaks at the following 2θ angles: 3.729±0.200°, 11.208±0.200°, 15.943±0.200°, 21.259±0.200°, and 23.480±0.200°.
[0166] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline form V has characteristic diffraction peaks at the following 2θ angles: 3.729±0.200°, 11.208±0.200°, 15.943±0.200°, 18.814±0.200°, 19.613±0.200°, 20.013±0.200°, 21.259±0.200°, and 23.480±0.200°.
[0167] In some embodiments of the present invention, the X-ray powder diffraction pattern of crystalline Form V has characteristic diffraction peaks at the following 2θ angles: 3.729°, 7.556°, 7.930°, 11.208°, 14.132°, 14.587°, 15.943°, 17.855°, 18.814°, 19.613°, 20.013°, 22.259°, 21.476°, 21.966°, 23.271°, 23.480°, 24.340°, 25.142°, 25.409°, 26.267°, 26.849°, and 27.469°.
[0168] In some embodiments of the present invention, the XRPD pattern of crystalline form V above is essentially as shown in FIG. In some embodiments of the present invention, the analytical data for the XRPD pattern of crystalline Form V above is shown in Table 22.
[0169] [Table 22] TIFF2024543227000044.tif30170
[0170] The present invention also provides the use of the above compound or crystalline form A, crystalline form B, crystalline form C, crystalline form D, crystalline form E, crystalline form F, crystalline form G, crystalline form H, crystalline form I, crystalline form J, crystalline form K, crystalline form L, crystalline form M, crystalline form N, crystalline form O, crystalline form P, crystalline form Q, crystalline form R, crystalline form S, crystalline form T, crystalline form U, crystalline form V in the preparation of a medicament for treating diabetes, weight loss, and NASH.
[0171] Definitions and Explanations Unless otherwise stated, the following terms and phrases used herein shall have the following meanings: Certain words or terms should not be considered uncertain or unclear without a specific definition, but should be understood in their ordinary sense. When a trade name is mentioned herein, it refers to the corresponding product or its active ingredient.
[0172] The intermediate compounds of the present application can be prepared by a variety of synthetic methods familiar to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining these specific embodiments with other chemical synthetic methods, and equivalent alternatives familiar to those skilled in the art. Preferred embodiments include, but are not limited to, examples of the present invention.
[0173] The chemical reactions in certain embodiments of the present invention are completed in a suitable solvent, which must be suitable for the chemical changes in the present invention and the reagents and materials required therefor. To obtain the compounds of the present invention, those skilled in the art may need to modify or select synthetic steps or reaction processes based on the existing embodiments.
[0174] The structure of the compound according to the present invention can be confirmed by conventional methods well known to those skilled in the art. When the present invention relates to the absolute configuration of a compound, the absolute configuration can be confirmed by conventional technical means in the art. For example, single crystal X-ray diffraction (SXRD) is used to collect diffraction intensity data of the cultured single crystal on a Bruker D8 venture diffractometer, the light source is CuKα radiation, and the scanning mode is φ / ω scanning. After collecting the relevant data, the absolute configuration can be confirmed by further analyzing the crystal structure by a direct method (Shelxs97).
[0175] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these. All of the solvents used in this invention are commercially available and can be used without further purification.
[0176] The solvents used in the present invention are commercially available. The following abbreviations are used in the present invention: aq stands for water; eq stands for equivalent; DCM stands for dichloromethane; PE stands for petroleum ether; DMF stands for N,N-dimethylformamide; DMSO stands for dimethylsulfoxide; MEK stands for butanone; EtOH stands for ethanol; MeOH stands for methanol; IPA stands for isopropanol; MTBE stands for methyl tert-butyl ether; THF stands for tetrahydrofuran; Pd(dppf)Cl 2 stands for [1,1-bis(diphenylphosphino)ferrocene]palladium dichloride. Pd(OH) 2 stands for palladium hydroxide, and LiAlH 4 stands for lithium aluminum hydride. Tris stands for trometamol.
[0177] Compounds are named according to general naming principles in the field or using ChemDraw® software; commercially available compounds are named according to the supplier's catalogue.
[0178] Technical effects The compound of the present invention has a stable crystalline form, is less susceptible to heat and humidity, has good in vivo efficacy, and is suitable for formulation. The compound of formula (I) exhibits a better ability to agonize the GLP-1 receptor.
[0179] X-ray powder diffractometer (XRPD) assay in the present invention 1. Equipment model: PANalytical X'Pert3 X-ray diffractometer Test method: Approximately 20mg of sample is used for XRPD detection. The detailed parameters are as follows:
[0180] [Table 23]
[0181] 2. X-ray diffraction patterns are obtained by a Bruker D2 Phaser. The instrument parameters are as follows:
[0182] [Table 24]
[0183] Differential Scanning Calorimetry (DSC) Assay in This Application
[0184] Instrument model: TA 2500 Differential Scanning Calorimeter The parameters and test methods are as follows:
[0185] [Table 25]
[0186] Thermogravimetric Analysis (TGA) Assay in the Present Invention
[0187] Instrument model: TA 5500 Thermogravimetric Analyzer The parameters and test methods are as follows:
[0188] [Table 26]
[0189] Dynamic Vapor Sorption (DVS) Assay for Use in the Present Invention
[0190] Dynamic vapor sorption (DVS) curves are collected by SMS (Surface Measurement Systems) with DVS Intrinsic plus. Relative humidity at 25 °C is measured using the following solubility curves: lithium chloride (LiCl), magnesium nitrate [Mg(NO 3 ) 2 ] and is calibrated by the deliquescence point of potassium chloride (KCl).
[0191] The test parameters are as follows:
[0192] [Table 27] The moisture absorption rating is classified as follows:
[0193] [Table 28] [Brief description of the drawings]
[0194] [Figure 1] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form A of compound of formula (II-1). [Diagram 2] 1 is a DSC thermogram of crystalline form A of compound of formula (II-1). [Diagram 3] 1 is a TGA spectrum of crystalline form A of compound of formula (II-1). [Figure 4] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form B of compound of formula (II). [Diagram 5] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form C of compound of formula (II). [Figure 6] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form D of compound of formula (II). [Figure 7] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form E of compound of formula (II). [Figure 8] FIG. 1 is a DSC thermogram of crystalline form E of compound of formula (II). [Figure 9] 1 is a TGA spectrum of crystalline form E of compound of formula (II). [Figure 10] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form F of compound of formula (II). [Figure 11] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form G of compound of formula (II). [Figure 12] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form H of compound of formula (II). [Figure 13] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form I of compound of formula (II). [Figure 14] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form J of compound of formula (III). [Figure 15] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form K of compound of formula (IV-I). [Figure 16] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form L of compound of formula (IV). [Figure 17] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form M of compound of formula (V). [Figure 18] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form N of compound of formula (VI). [Figure 19] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form O of compound of formula (VII). [Figure 20] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form P of compound of formula (VII). [Figure 21]FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form Q of compound of formula (VII). [Figure 22] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form R of compound of formula (I). [Diagram 23] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form S of compound of formula (I). [Figure 24] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form T of compound of formula (I-1). [Diagram 25] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form U of compound of formula (I-1). [Figure 26] FIG. 1 is an XRPD pattern of Cu-Kα radiation of crystalline form U of compound of formula (I). [Figure 27] 1 is a DVS spectrum of crystalline form A of compound of formula (II-1). [Figure 28] 1 is a DVS spectrum of crystalline form E of compound of formula (II). [Figure 29] 1 is a DVS spectrum of crystalline form Q of compound of formula (VIII). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0195] In order to better understand the present invention, the present invention will be further described below in conjunction with specific examples, but these specific examples are not intended to limit the present invention.
[0196] Example 1: Synthesis of compounds of formula (I)
[0197] [ka]
[0198] Step 1: Synthesis of compound B-1-3 B-1-1 (1.00 g, 6.23 mmol, 1 eq.) was added to a reaction flask containing THF (40 mL), and under nitrogen protection, NaH (375 mg, 9.38 mmol, content 60%, 1.51 eq.) was added at 0° C., heated to 22° C., and stirred for 1 hour. B-1-2 (1.5 g, 6.33 mmol, 1.02 eq.) was added, heated to 60° C., and stirred for 16 hours. The reaction solution was quenched by adding 20 mL of water, extracted by adding DCM (20 mL×3), and the organic phase was collected, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:0) to obtain B-1-3. LCMS: m / z = 317.8 [M+H] + .
[0199] Step 2: Synthesis of compound B-1-5 B-1-3 (1.50 g, 4.74 mmol, 1 equiv.), B-1-4 (1.50 g, 4.85 mmol, 1.02 equiv.), sodium carbonate (1.50 g, 14.15 mmol, 2.99 equiv.), dioxane (30 mL), and water (6 mL) were added to a reaction flask and the resulting mixture was stirred under a nitrogen atmosphere until Pd(dppf)Cl 2 (0.17 g, 232.33 μmol, 0.05 equivalents) was added and the reaction system was stirred at 100° C. for 3 hours. The reaction solution was concentrated to obtain a crude product, and then water (50 mL) was added and extracted with ethyl acetate (50 mL×3). The organic phases were then combined and washed with saturated aqueous sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The crude product was separated and purified by column chromatography (petroleum ether:ethyl acetate=1:0-20:1) to obtain B-1-5. LCMS: m / z = 419.2 [M+H] + .
[0200] Step 3: Synthesis of compound B-1 B-1-5 (1.80 g, 4.30 mmol, 1 equiv.) and anhydrous DCM (30 mL) were added to the reaction flask, trifluoroacetic acid (7.70 g, 67.53 mmol, 5.0 mL, 15.72 equiv.) was added, and the reaction system was stirred at 20° C. for 12 h. Sodium carbonate solution (30 mL) was added to the reaction solution, and solid sodium carbonate was added to adjust the pH of the solution to about 9-10, and extracted with ethyl acetate (30 mL×3). The combined organic phase was washed with saturated aqueous sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was separated and purified by column chromatography (DCM:MeOH=1:0-10:1) to obtain B-1. LCMS: m / z = 319.1 [M+H] + .
[0201] [ka]
[0202] Step 4: Synthesis of compound B-2-2 Compound B-2-1 (12 g, 67.33 mmol, 1 equivalent) was dissolved in THF (120 mL), purged with argon, and Pd(OH) 2 (6.00 g, 4.27 mmol, content 10%, 6.35e~2 equivalents) was added, hydrogen was injected at a pressure of 50 psi, and the mixture was stirred at 45 ° C for 24 hours. The reaction solution was filtered through diatomaceous earth and washed with anhydrous THF to obtain a THF solution of B-2-2, which was directly used for the next reaction without post-treatment. 1 H NMR (400 MHz, CDCl 3 ) δ ppm 7.10 -7.16 (m, 2 H), 7.03 -7.07 (m, 2 H), 4.75 -4.83 (m, 1 H), 4.52 -4.61 (m, 1 H), 4.39 -4.46 (m, 1 H).
[0203] Step 5: Synthesis of compound B-2 Compound B-2-2 (2 g, 22.70 mmol, 1 eq.) and TEA (13.78 g, 136.20 mmol, 18.96 mL, 6 eq.) were added to the reaction flask, and the flask was evacuated with a pump and replaced with nitrogen. Then, methanesulfonic anhydride (11.86 g, 68.10 mmol, 2.64 mL, 3 eq.) was added in several portions at 0 ° C., and the temperature was then raised to 25 ° C. and reacted for 24 hours. Water (125 mL) was poured into the reaction solution to quench the reaction, the organic phase was separated, and the aqueous phase was extracted with ethyl acetate (50 mL). The organic phases were combined, washed with saturated saline (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure at 45 ° C. using a water pump to obtain a crude product. The crude product was separated and purified by column chromatography (PE:EA = 1:0 to 1:1, gradient elution) to obtain B-2. 1 H NMR (400 MHz, CDC l3 ) δ ppm 4.99 -5.05 (m, 1 H) , 4.64 -4.71 (m, 1 H) , 4.57 (dt, J=9.10, 6.08 Hz, 1 H) , 4.36 (d, J=3.88 Hz, 2 H) , 3.10 (s, 3 H) , 2.70 -2.81 (m, 1 H), 2.58 -2.68 (m, 1 H).
[0204] [ka]
[0205] Step 6: Synthesis of Compound 1-2 Compound 1-1 (23 g, 164.12 mmol, 1 equivalent) and DMF (115 mL) were added to a reaction flask, purged with nitrogen, and cooled to 0°C. NaH (9.85 g, 246.18 mmol, 60% content, 1.5 equivalents) was then added, purged with nitrogen again, and 2-(trimethylsilyl)ethoxymethyl chloride (41.04 g, 246.18 mmol, 43.57 mL, 1.5 equivalents) was added dropwise. After the addition was completed, the temperature was raised to 25°C and the reaction was carried out for 12 hours. The reaction solution was quenched with ice water (500 mL) and extracted with ethyl acetate (200 mL x 3). The organic phases were combined, washed with saturated saline (200 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure at 45°C using a water pump to obtain a crude product. The crude product was separated and purified by column chromatography (PE:EA=1:0 to 1:1, gradient elution) to obtain 1-2. 1 H NMR (400 MHz, CDCl 3 ) δ ppm 7.24 (d, J=0.63 Hz, 1 H) , 7.17 (s, 1 H) , 5.76 (s, 2 H) , 4.39 (q, J=7.13 Hz, 2 H) , 3.49 -3.56 (m, 2 H) , 1.40 (t, J=7.13 Hz, 3 H), 0.86 -0.93 (m, 2 H), -0.07 --0.04 (m, 9 H).
[0206] Step 7: Synthesis of Compounds 1-3 THF (1000 mL) was added to the reaction flask and LiAlH 4 (6.04g, 159.21mmol, 1.5eq) was added in portions, purged with nitrogen, cooled to 0°C, stirred for 15 minutes, and then compound 1-2 (28.7g, 106.14mmol, 1eq) was added at 0°C, heated to 25°C, and reacted for 0.5 hours. The reaction solution was cooled to 0°C, and 6mL of water, 6mL of 15% sodium hydroxide, and 18mL of water were added in sequence, heated to 25°C, stirred for 15 minutes, and then anhydrous magnesium sulfate was added and stirred for 15 minutes. The filtrate was collected by filtration, washed with saturated saline (500mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure at 45°C using a water pump to obtain compound 1-3.1 H NMR (400 MHz, CDCl 3 ) δ ppm 6.98 (d, J=1.13 Hz, 1 H) , 6.93 (d, J=1.13 Hz, 1 H) , 5.37 (s, 2 H) , 4.72 (s, 2 H) , 3.52 (dd, J=8.76, 7.75 Hz, 2 H) , 0.89 -0.95 (m, 2 H), -0.02 --0.01 (m, 9 H).
[0207] Step 8: Synthesis of Compounds 1-4 Compound 1-3 (18.81 g, 82.37 mmol, 1 equivalent), tert-butyldiphenylchlorosilane (27.17 g, 98.84 mmol, 25.39 mL, 1.2 equivalent), imidazole (14.02 g, 205.92 mmol, 2.5 equivalent), and DMF (188 mL) were added to a reaction flask, substituted with nitrogen, and reacted at 25 ° C for 16 hours. Water (1000 mL) was poured into the reaction liquid to quench, ethyl acetate (200 mL × 3) was added for extraction, the organic phase was combined, washed with saturated saline (200 mL × 3), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure at 45 ° C using a water pump to obtain a crude product. The crude product was separated and purified by column chromatography (PE:EA = 1:0 to 1:1, gradient elution) to obtain 1-4. 1 H NMR (400 MHz, CDCl 3 ) δ ppm 7.66 -7.72 (m, 4 H) , 7.37 -7.46 (m, 6 H) , 6.96 -7.02 (m, 2 H) , 5.41 (s, 2 H) , 4.84 (s, 2 H) , 3.41 -3.48 (m, 2 H) , 1.06 (s, 9 H), 0.85 -0.91 (m, 2 H), -0.03 (s, 9 H).
[0208] Step 9: Synthesis of Compounds 1-5 Compound 1-4 (22 g, 47.13 mmol, 1 eq.) and THF (440 mL) were added to the reaction flask, and the flask was evacuated with a pump and replaced with nitrogen. N-bromosuccinimide (25.17 g, 141.40 mmol, 44.18 μL, 3 eq.) was added in portions at 0° C., and the temperature was then raised to 25° C. for 12 hours. The reaction solution was quenched with water (440 mL), extracted with ethyl acetate (2200 mL×2), and the combined organic phase was washed with saturated saline (2200 mL×1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure at 30° C. using a water pump to obtain a crude product. The crude product was separated and purified by column chromatography (PE:EA=1:1 to 2:1, gradient elution) to obtain 1-5. 1 H NMR (400 MHz, CDCl 3 ) δ ppm 7.64 -7.67 (m, 4 H) , 7.37 -7.48 (m, 6 H) , 5.44 (s, 2 H) , 4.80 (s, 2 H) , 3.45 -3.51 (m, 2 H) , 1.07 (s, 9 H) , 0.85 -0.90 (m, 2 H), -0.02 (s, 9 H).
[0209] Step 10: Synthesis of Compounds 1-6 Compound 1-5 (6 g, 9.61 mmol, 1 eq) and THF (60 mL) were added to a reaction flask, purged with nitrogen, cooled to -40 ° C, i-PrMgCl-LiCl (1.3 M, 8.13 mL, 1.1 eq) was added dropwise and stirred for 1.5 hours, then DMF (61.62 g, 843.09 mmol, 64.86 mL, 87.76 eq) was added dropwise, heated to 25 ° C, and continued to stir for 30 minutes. The reaction solution was quenched with water (120 mL), extracted with ethyl acetate (50 mL × 2), the organic phase was combined, washed with saturated saline (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure at 45 ° C using a water pump to obtain a crude product. The crude product was separated and purified by column chromatography (PE:EA = 1:0 to 10:1, gradient elution) to obtain 1-6. 1 H NMR (400 MHz, CDCl 3) δ ppm 9.76 (s, 1 H) , 7.64 -7.68 (m, 5 H) , 7.38 -7.42 (m, 5 H) , 5.85 (s, 2 H) , 4.86 (s, 2 H) , 3.49 -3.54 (m, 2 H) , 1.07 (s, 9 H) , 0.84 -0.88 (m, 2 H) , -0.03 (s, 9 H).
[0210] Step 11: Synthesis of Compounds 1-8 Compound 1-6 (1.23 g, 2.14 mmol, 1 equivalent) was dissolved in EtOH (61.5 mL), sodium ethoxide (2.19 g, 6.43 mmol, content 20%, 3 equivalents) and compound 1-7 (273.10 mg, 2.57 mmol, 233.42 μL, 1.2 equivalents) were added, and the mixture was stirred at 20 ° C for 2 hours, then heated to 80 ° C and stirred for 12 hours. The reaction solution was quenched with water (50 mL), extracted twice with ethyl acetate (25 mL), the organic phase was combined, washed with saturated saline (50 mL), filtered, and the filtrate was then concentrated under reduced pressure at 45 ° C using a water pump to obtain a crude product. The crude product was separated and purified by column chromatography (PE:EA = 1:0 to 10:1, gradient elution) to obtain compound 1-8. 1 H NMR (400 MHz, CDCl 3 ) δ ppm 7.72 (s, 1 H) , 5.54 (s, 2 H) , 4.91 (s, 2 H) , 4.39 (q, J=7.13 Hz, 2 H) , 3.55 -3.61 (m, 2 H) , 2.30 -2.64 (m, 1 H) , 1.40 (t, J=7.13 Hz, 3 H), 0.91 -0.96 (m, 2 H), -0.02 (s, 9 H).
[0211] Step 12: Synthesis of Compounds 1-9 Compound 1-8 (120 mg, 336.59 μmol, 1 equivalent), triethylamine (102.18 mg, 1.01 mmol, 140.55 μL, 3 equivalents) and DCM (2 mL) were added to a reaction flask, and the flask was evacuated with a pump and replaced with nitrogen. Then, methylsulfonyl chloride (57.84 mg, 504.89 μmol, 39.08 μL, 1.5 equivalents) was added in portions at 0°C, and the temperature was then raised to 25°C and reacted for 12 hours. The reaction solution was concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by silica gel thin layer chromatography (DCM:MeOH=20:1) to obtain compound 1-9. 1 H NMR (400 MHz, CDCl 3 ) δ ppm 7.72 (s, 1 H) , 5.57 (s, 2 H) , 4.85 (s, 2 H) , 4.39 (q, J=7.13 Hz, 2 H) , 3.56 -3.61 (m, 2 H) , 1.40 (t, J=7.13 Hz, 3 H) , 0.92 -0.97 (m, 2 H), -0.02 (s, 9 H).
[0212] Step 13: Synthesis of Compounds 1-10 Compound 1-9 (0.16 g, 426.72 μmol, 1 equivalent), compound B-1 (0.30 g, 941.11 μmol, 2.21 equivalent), potassium carbonate (0.10 g, 723.56 μmol, 1.70 equivalent) and acetonitrile (10 mL) were added to the reaction flask in this order, and the reaction system was stirred at 60 ° C. for 10 hours. The reaction solution was concentrated to obtain a crude product, water (10 mL) was added, and the mixture was extracted with ethyl acetate (10 mL × 3), and the organic phases were combined and washed with saturated sodium chloride aqueous solution (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The crude product was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1: 0 to 5: 1) to obtain compound 1-10. LCMS: m / z = 657.3 [M + H] + ; 1 H NMR (400 MHz, CDCl 3) δ ppm 7.74 (s, 1 H) , 7.55 (t, J=7.91 Hz, 1 H) , 7.43 (t, J=8.03 Hz, 1 H) , 7.08 -7.17 (m, 2 H) , 6.94 (d, J=7.28 Hz, 1 H) , 6.72 (br s, 1 H) , 6.66 (d, J=8.28 Hz, 1 H) , 5.66 (s, 2 H) , 5.43 (s, 2 H) , 4.38 (q, J=7.03 Hz, 2 H) , 3.95 (s, 2 H) , 3.52 -3.57 (m, 2 H) , 3.29 (br s, 2 H), 2.79 -2.85 (m, 2 H), 2.61 (br s, 2 H), 1.40 (t, J=7.03 Hz, 3 H), 0.89 -0.94 (m, 2 H), -0.10 --0.03 (m, 9 H).
[0213] Step 14: Synthesis of Compounds 1-11 Compound 1-10 (0.30 g, 456.43 μmol, 1 equiv.) and anhydrous DCM (5.0 mL) were added to the reaction flask in order, followed by trifluoroacetic acid (1.54 g, 13.51 mmol, 1.0 mL, 29.59 equiv.). The reaction system was stirred at 40° C. for 5 h. Sodium carbonate solution (10 mL) was added to the reaction solution, and solid sodium carbonate was added to adjust the pH of the solution to about 9-10, and extracted with ethyl acetate (10 mL×3). The combined organic phase was then washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the crude product. The crude product was separated and purified by column chromatography (petroleum ether:ethyl acetate=10:1-1:1) to obtain 1-11. LCMS: m / z = 527.2 [M+H]+; 1 H NMR (400 MHz, CDCl 3) δ ppm 10.08 (br s, 1 H) , 7.68 (br s, 1 H) , 7.57 (t, J=7.78 Hz, 1 H) , 7.43 (t, J=8.16 Hz, 1 H) , 7.09 -7.17 (m, 2 H) , 6.96 (d, J=7.53 Hz, 1 H) , 6.73 (br s, 1 H) , 6.69 (d, J=8.28 Hz, 1 H) , 5.44 (s, 2 H) , 4.37 (q, J=7.11 Hz, 2 H) , 3.96 (s, 2 H) , 3.35 (br d, J=3.01 Hz, 2 H), 2.83 -2.91 (m, 2 H), 2.68 (br s, 2 H), 1.39 (t, J=7.15 Hz, 3 H).
[0214] Step 15: Synthesis of Compounds 1-12 and 1-13 Compound 1-11 (0.20 g, 379.50 μmol, 1 equivalent), B-2 (0.35 g, 2.11 mmol, 5.55 equivalent), potassium carbonate (0.40 g, 1.23 mmol, 3.23 equivalent) and acetonitrile (5 mL) were added to the reaction flask in order, and the reaction system was stirred at 80 ° C for 10 hours. The reaction solution was concentrated to obtain a crude product, water (10 mL) was added, and the mixture was extracted with ethyl acetate (10 mL × 3), and the organic phases were combined and washed with saturated aqueous sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a crude product. The crude product was separated and purified by column chromatography (petroleum ether: ethyl acetate = 1:0 to 1:1) to obtain a mixture of compounds 1-12 and 1-13. LCMS (retention time: 3.508): m / z = 597.1 [M + H] + ; LCMS (retention time: 3.566) : m / z = 597.3 [M+H] + .
[0215] Step 16: Synthesis of Compounds of Formula (I) A mixture of compounds 1-12 and 1-13 (90 mg, 150.73 μmol, 1 equivalent), water (0.4 mL), and acetonitrile (2 mL) were added to a reaction flask in this order, and 1,5,7-triazabicyclo(4.4.0)dec-5-ene (50 mg, 359.20 μmol, 2.38 equivalents) was added, and the reaction system was stirred at 20°C for 10 hours. The reaction solution was concentrated to obtain a crude product. The crude product was separated and purified by TLC (DCM:MeOH=10:1) to obtain a mixture, which was then purified by supercritical fluid chromatography (column: DAICEL CHIRALPAK IG (250 mm×30 mm, 10 μm); mobile phase: [0.1% NH 3 H 2 OMeOH];CO 2 : 55%-55%, min) to give the compound of formula (I) (retention time: 6.815 min).
[0216] Detection method (chromatography column: Chiralpak IG-3 50iA inner diameter 4.6 mm, 3 μm. Mobile phase: A:CO 2 B: methanol (0.05% diethylamine), isocratic elution: methanol (0.05% diethylamine) 40%, flow rate: 4 mL / min, column temperature: 35°C, back pressure: 1500 psi). LCMS: m / z = 569.2 [M+H]+; 1 H NMR (400 MHz, DMSO-d 6) δ ppm 7.68 (t, J=7.91 Hz, 1 H) , 7.55 (t, J=8.16 Hz, 1 H) , 7.40 -7.50 (m, 2 H) , 7.30 (dd, J=8.28, 1.76 Hz, 1 H) , 7.08 (d, J=7.53 Hz, 1 H) , 6.68 -6.77 (m, 2 H) , 5.39 (s, 2 H) , 4.97 -5.08 (m, 1 H) , 4.52 -4.60 (m, 1 H) , 4.40 -4.50 (m, 2 H) , 4.28 -4.38 (m, 1 H) , 3.74 -3.92 (m, 2 H) , 3.18 (br s, 2 H) , 2.68 (br d, J=5.52 Hz, 2 H) , 2.58 -2.66 (m, 1 H) , 2.32 -2.38 (m, 1 H); 1 H NMR (400 MHz, CD 3 OD) δ ppm 7.64 (s, 1 H), 7.62 (t, J=7.91 Hz, 1 H), 7.48 (t, J=8.03 Hz, 1 H), 7.16 -7.24 (m, 2 H), 7.05 (d, J=7.53 Hz, 1 H), 6.71 (br s, 1 H) , 6.68 (d, J=8.03 Hz, 1 H) , 5.42 (s, 2 H) , 5.19 (br d, J=4.27 Hz, 2 H) , 4.36 -4.45 (m, 1 H) , 3.93 -4.05 (m, 2 H) , 2.82 -2.90 (m, 2H), 2.68 -2.76 (m, 1 H), 2.63 (br s, 2 H), 2.48 (br d, J=8.78 Hz, 1 H).
[0217] Two-dimensional nuclear magnetic resonance NOE revealed that C 8 -H is C 10 -H, and the structure of the product is confirmed to be correct.
[0218] [ka]
[0219] Example 2: Preparation of Crystalline Forms Preparation of crystalline form A: Trometamol (1.31g, 10.8mmol, 1.02eq) and methanol (30mL) were added to the reaction flask in sequence, then the system was stirred at 50°C to dissolve until transparent, cooled to 25°C, the compound of formula (I) (6g, 10.54mmol, 1eq) was added, and the system was stirred to dissolve until transparent. 90mL of methyl tert-butyl ether was added, stirred at 25°C for 16 hours, filtered, and the filter cake was washed three times with 12mL of a mixed solvent of methanol:methyl tert-butyl ether=1:3, transferred, and dried in vacuum at 50°C for 16 hours to obtain the crystalline form A of the compound of formula (II-1). 1 H NMR (400 MHz, CD 3 OD)δ ppm 7.57 -7.68 (m, 2 H) 7.50 (t, J=7.91 Hz, 1 H) 7.16 -7.28 (m, 2 H) 7.06 (d, J=7.53 Hz, 1 H) 6.63 -6.79 (m, 2 H) 5 . 44 (s, 2 H) 5.15 -5.28 (m, 1 H) 4.55 -4.80 (m, 3 H) 4.44 (dt, J=9.29, 6.02 Hz, 1 H) 3.89 -4.04 (m, 2 H) 3.68 (s, 6 H) 3.26 (br s, 2 H) 2.68 -2.86 (m, 3 H) 2.63 (br s, 2 H) 2.43 -2.55 (m, 1 H).
[0220] Preparation of crystalline form B: Approximately 15 mg of crystalline form A of the compound of formula (II-1) was weighed into an HPLC glass vial, and then 0.5 mL of H 2 O was added. The resulting cloudy solution was magnetically stirred (1000 rpm) at room temperature for about 4 days and then centrifuged to collect the solid to obtain crystalline form B of the compound of formula (II). The sample was opened and dried at room temperature overnight, after which it transformed to crystalline form E.
[0221] Preparation of crystalline form C: Approximately 15 mg of the compound of formula (I) and an equimolar ratio of Tris (3 mg) were weighed into an HPLC glass vial, followed by the addition of 0.5 mL of EtOH. The resulting cloudy solution was magnetically stirred (1000 rpm) at room temperature for approximately 4 days, then centrifuged to collect the solid, yielding crystalline form C of the compound of formula (II). The sample was opened and dried at room temperature overnight, after which it transformed into crystalline form E.
[0222] Preparation of crystalline form D: About 15 mg of crystalline form A of compound of formula (II-1) was weighed into a 3 mL vial, then 1.0 mL of MeOH / MTBE (1:1, v / v) was added and stirred at 50° C. for about 1 hour for equilibration. The supernatant was obtained by filtration, and the resulting supernatant was placed in a biochemical incubator and cooled from 50° C. to 5° C. at 0.1° C. / min and kept at 5° C. The precipitated solid was collected to obtain crystalline form D of compound of formula (II). The sample was opened and dried at room temperature overnight, and then transformed into crystalline form E.
[0223] Preparation of crystalline form E: Approximately 15 mg of crystalline form A of compound of formula (II-1) was weighed into an HPLC glass vial, then 0.5 mL of IPA was added, and the resulting suspension was subjected to magnetic stirring (1000 rpm) under temperature cycling conditions (40°C to 5°C, 0.1°C / min, 2 cycles), and then centrifuged to collect the solid, yielding crystalline form E of compound of formula (II). 1 H NMR (400 MHz, CD 3OD) δ ppm 7.59 -7.64 (m, 2 H) 7.50 (t, J=8.03 Hz, 1 H) 7.21 (t, J=10.16 Hz, 2 H) 7.06 (d, J=7.28 Hz, 1 H) 6.72 -6.75 (m, 1 H) 6.68 (d, J=8.29 Hz, 1 H) 5.44 (s, 2 H) 5.21 (qd, J=7.03, 3.01 Hz, 1 H) 4.55 -4.73 (m, 3 H) 4.4 4 (dt, J=9.03, 6.02 Hz, 1 H) 3.91 -4.01 (m, 2 H) 3.68 (s, 6H) 3.26 (br s, 2 H) 2.70 -2.84 (m, 3 H) 2.63 (br s, 2 H) 2.40 -2.54 (m, 1 H).
[0224] Preparation of crystalline form F: Approximately 15 mg of crystalline form A of compound of formula (II-1) was weighed and added to a 20 mL vial, and then the solid was completely dissolved in 0.2-1.0 mL of MeOH (undissolved sample was filtered through a 0.45 μm PTFE filter to obtain a clear solution). MTBE was added dropwise to the obtained clear solution with stirring (1000 rpm) until solids precipitated, obtaining crystalline form F of compound of formula (II). The sample was opened and dried at room temperature overnight, after which it was transformed into crystalline form E.
[0225] Preparation of crystalline form G: Approximately 15 mg of crystalline form A of compound of formula (II-1) was weighed into a 3 mL vial, approximately 3 mL of EtOH was added into another 20 mL vial, and then the 3 mL vial was opened and placed into the 20 mL vial. The 20 mL vial was then sealed and left at room temperature for 7 days, after which the solid was collected to obtain crystalline form G of compound of formula (II). The sample was opened and dried at room temperature overnight, after which it transformed into crystalline form E.
[0226] Preparation of crystalline form H: About 15 mg of crystalline form A of compound of formula (II-1) was weighed into a 3 mL vial, about 3 mL of THF was added into another 20 mL vial, and then the 3 mL vial was opened and placed into the 20 mL vial. The 20 mL vial was then sealed and left at room temperature for 7 days, after which the solid was collected to obtain crystalline form H of compound of formula (II). The sample was opened and dried at room temperature overnight, after which it transformed into crystalline form E.
[0227] Preparation of crystalline form I: Approximately 15 mg of crystalline form A of the compound of formula (II-1) was weighed into an HPLC glass vial, and then 0.5 mL of H 2 O was added and the resulting suspension was magnetically stirred (1000 rpm) under temperature cycling conditions (40 °C to 5 °C, 0.1 °C / min, 2 cycles). The solid was then collected by centrifugation to obtain crystalline form I of compound of formula (II). The sample was opened and dried at room temperature overnight, after which it transformed into crystalline form E.
[0228] Preparation of crystalline form J: About 50 mg of the compound of formula (I) was weighed and dissolved in 0.8 mL of butanone, and then 0.9 mL of 0.1 mol / L phosphoric acid-MEK solution was added at 50° C. The solid was first dissolved and precipitated at 50° C. until transparent, then stirred at 50° C. for 1 hour, and then cooled slowly to 18° C. (about 0.5 K / min). After stirring at 18° C. for about 18 hours, the solid was filtered to obtain it, and dried at 50° C. for 3-4 hours to obtain the crystalline form J of the compound of formula (III).
[0229] Preparation of crystalline form K: Approximately 50 mg of the compound of formula (I) was weighed and dissolved in 0.4 mL of butanone, and 0.9 mL of a 0.1 mol / L methanol solution of oxalic acid was added at 50°C. The mixture was dissolved at 50°C until it became transparent, and cooled to 18°C without precipitation. 3.0 mL of n-heptane was added to separate the phases. After stirring at 18°C for approximately 18 hours, the solid was precipitated, filtered to obtain the solid, and dried at 50°C for 3 to 4 hours to obtain the crystalline form K of the compound of formula (IV).
[0230] Preparation of crystalline form L: Approximately 50 mg of compound of formula (I) was weighed and dissolved in 1.0 mL of ethyl acetate, then 8.43 mg of solid oxalic acid was added at 50° C. A white solid precipitated at 50° C., then stirred at 50° C. for 1 hour to form an oil. It was slowly cooled to 18° C. and stirred at 18° C. for about 18 hours to turn into a solid, then filtered to obtain the solid, which was dried at 50° C. for 3-4 hours to obtain crystalline form L of compound of formula (IV).
[0231] Preparation of crystalline form M: Approximately 50 mg of the compound of formula (I) was weighed and dissolved in 1.2 mL of butanone, then 10.18 mg of maleic acid was added at 18°C to precipitate a white solid, and stirring was continued for approximately 18 hours. The solid was obtained by filtration and dried at 50°C for 3-4 hours to obtain crystalline form M of the compound of formula (V).
[0232] Preparation of crystalline form N: Approximately 50 mg of the compound of formula (I) was weighed and dissolved in 0.4 mL of butanone, and 0.9 mL of p-toluenesulfonic acid solution (0.1 mol / L methanol solution) was added at 18°C, and the mixture was stirred for approximately 18 hours. After adding 1.0 mL of n-heptane without precipitation, a solid was precipitated, filtered to obtain a solid, and dried at 50°C for 3 to 4 hours to obtain the crystalline form N of the compound of formula (VI).
[0233] Preparation of crystalline form O: Approximately 50 mg of the compound of formula (I) was weighed and dissolved in 0.8 mL of butanone, and 0.9 mL of L-arginine solution (0.1 mol / L methanol solution) was added at 18°C. The solution was dissolved until it became transparent, and then a white solid precipitated immediately. The mixture was stirred for approximately 18 hours. The solid was filtered and dried at 50°C for 3 to 4 hours to obtain the crystalline form O of the compound of formula (VII). 1H NMR (400 MHz, CD3OD) δ ppm 7.60 (t, J=7.78 Hz, 1 H) 7.57 (s, 1 H) 7.48 (t, J=8.11 Hz, 1 H) 7.15 -7.23 (m, 2 H) 7.04 (d, J=7.45 Hz, 1 H) 6.71 (br s, 1 H) 6.66 (d, J=8.33 Hz, 1 H) 5.42 (s, 2 H) 5.13 -5.24 (m, 1 H) 4.51 -4.71 (m, 3 H) 4.41 (dt, J=9.15, 5.95 Hz, 1 H) 3.87 -4.06 (m, 3 H) 3.82 (dd, J=4.82, 1.75 Hz, 1 H) 3.73 -3.80 (m, 1 H) 3.60 -3.71 (m, 3 H) 3.24 (br s, 2 H) 3.15 (d, J=6.14 Hz, 2 H) 2.76 -2.84 (m, 2 H) 2.66 -2.75 (m, 4 H) 2.61 (br s, 2 H) 2.40 -2.52 (m, 1 H).
[0234] Preparation of crystalline form P: Approximately 50 mg of the compound of formula (I) was weighed and dissolved in 1.4 mL of acetonitrile, and 0.9 mL of L-arginine solution (0.1 mol / L methanol solution) was added at 18°C. The solution was dissolved until it became transparent, and then a white solid precipitated immediately. The mixture was stirred for approximately 18 hours. The solid was filtered and dried at 50°C for 3 to 4 hours to obtain the crystalline form P of the compound of formula (VII).
[0235] Preparation of crystalline form Q: Approximately 50 mg of the compound of formula (I) was weighed and dissolved in 1.0 mL of acetonitrile, and 0.9 mL of meglumine solution (0.1 mol / L methanol solution) was added at 18°C. The solution was dissolved until it became transparent, and then 2.0 mL of methyl tert-butyl ether was added. After stirring for about 10 minutes, a solid precipitated, and stirring was continued for about 18 hours. The solid was obtained by filtration and dried at 50°C for 3 to 4 hours to obtain the crystalline form Q of the compound of formula (VIII).
[0236] Preparation of crystalline form R: About 50 mg of the compound of formula (I) was weighed and dissolved in 0.6 mL of tetrahydrofuran. 0.8 mL of acetonitrile was slowly added to the solution at 17° C., and then a solid precipitated. The solid was filtered to obtain R-form crystals of the compound of formula (I).
[0237] Preparation of crystalline form S: Approximately 50 mg of the compound of formula (I) was weighed and dissolved in 0.2 mL of tetrahydrofuran at 50° C., stirred at 50° C. for a certain period of time, and then cooled to 20° C. at a constant cooling rate. A solid precipitated and was filtered to obtain crystalline form S of the compound of formula (I).
[0238] Preparation of crystalline form T: Approximately 50 mg of the compound of formula (I) was weighed out, 0.8 mL of methanol was added, and the system was kept in a state of suspension and stirring at 20°C. After a certain period of time, the solid was filtered to obtain crystalline form T of the compound of formula (I-1).
[0239] Preparation of crystalline form U: Approximately 50 mg of the compound of formula (I) was weighed out, 0.8 mL of ethyl acetate was added, and the system was kept in a state of suspension and stirring at 20°C. After a certain period of time, the solid was filtered to obtain crystalline form U of the compound of formula (I-1).
[0240] Preparation of crystalline form V: Approximately 50 mg of the compound of formula (I) was weighed out, 0.6 mL of acetonitrile was added, and the system was kept in a state of suspension and stirring at 50° C. After a certain period of time, the solid was filtered to obtain crystalline form V of the compound of formula (I).
[0241] Example 3: Study of the hygroscopicity of the crystalline form Using an SMS Intrinsic dynamic vapor sorption instrument, 10 mg of each of the crystalline form A of the compound of formula (II-1), the crystalline form E of the compound of formula (II), and the crystalline form Q of the compound of formula (VIII) were sampled and placed on a DVS sample disk for testing. Specific results are shown as DVS spectra in Figures 27 to 29.
[0242] As can be seen from the above, the weight gain due to moisture absorption of the crystalline form A of the compound of formula (II-1) at 25°C and 80% RH is 2.20%, and the crystalline form A is hygroscopic. The crystalline form changes before and after adsorption and desorption. The weight gain due to moisture absorption of the crystalline form E of the compound of formula (II) at 25°C and 80% RH is 2.20%, and the crystalline form E is hygroscopic. The crystalline form changes before and after adsorption and desorption. The weight gain due to moisture absorption of the crystalline form Q of the compound of formula (VIII) at 25°C and 80% RH is 1.08%, and the crystalline form Q is slightly hygroscopic. The crystalline form does not change before and after adsorption and desorption.
[0243] Example 4: Study on the solid state stability of crystalline form E of compound of formula (II) 500 mg of crystalline form E of compound of formula (II) was weighed and placed on the bottom of a glass sample flask, then spread into a thin layer. The crystalline form E was placed under accelerated conditions (40°C / 75%RH and 60°C / 75%RH) and the sample was fully exposed. Samples were taken from crystalline form E on the 5th day, 15th day, 1st month and 2nd month for XRPD detection, and the detection results were compared with the initial test results on the 0th day. The experimental results are shown in Table 23 below.
[0244] [Table 29]
[0245] Conclusion: The crystalline form E of compound of formula (II) has good stability. Example 5: Study on the solid state stability of crystalline form Q of compound of formula (VIII) 500 mg of crystalline form Q of compound of formula (VIII) was weighed and placed on the bottom of a glass sample flask, then spread into a thin layer. The crystalline form was placed under accelerated conditions (40°C / 75%RH and 60°C / 75%RH) until the sample was fully exposed. Samples were taken from the crystalline form for XRPD detection on the 5th day, 15th day, and 1 month, and the detection results were compared with the initial test results on the 0th day. The experimental results are shown in Table 24 below.
[0246] [Table 30]
[0247] Conclusion: The crystalline form Q of the compound of formula (VIII) has good stability. Experimental Example 1: Detection of cell viability in vitro 1.Material 1) Cell line The cells were constructed by Shanghai Wuxi AppTec Co., Ltd. The details are shown in the following table.
[0248] [Table 31] 2) Reagents
[0249] [Table 32] 3)Equipment OptiPlate-384, white, PerkinElmer (catalog number 6007290); Echo, 384-well plate from Labcyte (catalog number P-05525); EnVision, PerkinElmer; Vi-Cell Counter, Beckman (catalog number Vi-CELL™ XR Cell Viability Analyzer) 4) Compound information
[0250] Compounds were prepared in DMSO to a working concentration of 30 μM, and the working volume of each sample was 5 μL in this study. 2. Method 1) Experimental materials Experimental Buffer
[0251] [Table 33]
[0252] Preparation of detection reagents Preparation of cAMP detection reagent: 250 μL of cAMP-D2 and 250 μL of anti-cAMP cryptate reagent were added to 4 mL of lysis buffer and mixed gently and thoroughly. 2) Experimental Method a) Preparation of compound plates: Compounds to be tested were diluted 10-point 3-fold with an initial concentration of 30 μM and the dilutions were completed by Bravo.
[0253] The reference compound exenatide was diluted 10-point 3-fold with an initial concentration of 500 nM and the dilutions were completed by Bravo. b) Compound transfer: 1) 100 nL of compound was transferred to an OptiPlate-384 plate using Echo. 2) The OptiPlate-384 plate was centrifuged at 1000 rpm for 5 seconds. c) Preparation of cell suspension 1) The GLP-1 cell cryopreservation tube was quickly thawed in 37°C warm water. 2) The cell suspension was transferred to a 15 mL transfer centrifuge tube and gently rinsed with 10 mL of HBSS. 3) The centrifuge tube was centrifuged at room temperature and 1000 rpm for 1 minute. 4) The supernatant was discarded. 5) The cells at the bottom were gently dispersed and washed with 10 mL of HBSS, then centrifuged to obtain cell pellets, and the cells were resuspended in the experiment buffer. 6) Cell density and viability were measured using a Vi-cell counter. 7) GLP-1 cells were diluted to 2.0 × 10 in experimental buffer. 5 / mL. 8) 100 nL of the diluted cell suspension was transferred to an OptiPlate-384 plate. 9) The cells were incubated at room temperature for 30 minutes. d) Addition of detection reagent: 1) 10 μL of 800 nM gradient diluted cAMP standard was added to empty wells of an OptiPlate-384 plate. 2) 10 μL of cAMP detection reagent was added. 3) The OptiPlate-384 plate was covered with TopSeal-A film and incubated at room temperature for 60 minutes.
[0254] The TopSeal-A was removed and the plate was read on an EnVision microplate reader. The experimental results are shown in Table 25 below.
[0255] [Table 34]
[0256] Conclusion: The compounds of the present invention show superior ability to agonize the GLP-1 receptor.
[0257] Experimental Example 2: Study on DMPK in rats Purpose of the experiment: Male SD rats were used as test animals. After a single dose, the plasma concentration of the compound was measured and the pharmacokinetic behavior was evaluated.
[0258] Experimental Procedure: Two healthy adult male SD rats were selected for the oral administration group. In the oral administration group, the vehicle was 20% PEG400 / 10% Solutol / 70% water. After the compound to be tested was mixed with the vehicle, a clear solution of 0.5 mg / mL was prepared by vortexing and ultrasonication. After the rats were orally administered with 5 mg / kg, the whole blood of the rats was collected for a certain period of time to prepare plasma. The drug concentration was analyzed by LC-MS / MS method, and the pharmacokinetic parameters were calculated by Phoenix WinNonlin software (Pharsight, USA). The experimental results are shown in Table 26 below.
[0259] [Table 35]
[0260] Conclusion: The crystalline form of the compound of the present invention exhibits high oral exposure, excellent oral bioavailability and favorable pharmacokinetic properties as an oral drug.
[0261] Experimental Example 3: Study on DMPK in cynomolgus monkeys Purpose of the experiment: Male cynomolgus monkeys were used as test animals. After a single dose, the plasma concentration of the compound was measured and the pharmacokinetic behavior was evaluated.
[0262] Experimental Procedure: Two healthy male cynomolgus monkeys were selected as a group. In the oral administration group, the vehicle was 20% HP-β-CD aqueous solution. After the test compound was mixed with the vehicle, a nearly transparent solution of 4 mg / mL was prepared by vortexing and ultrasonication. After oral administration of 20 mg / kg, whole blood of the cynomolgus monkey was collected for a certain period of time to prepare plasma. The drug concentration was analyzed by LC-MS / MS method, and the pharmacokinetic parameters were calculated by Phoenix WinNonlin software (Pharsight, USA). The experimental results are shown in Table 27 below.
[0263] [Table 36]
[0264] Conclusion: The crystalline form of the compound of the present invention has high oral exposure and excellent oral bioavailability, the in vivo exposure of the crystalline form is significantly higher than that of the free form, and it shows good pharmacokinetic properties as an oral drug.
Claims
1. Compounds of formula (O) or formula (I) and pharma- ceutically acceptable salts thereof, [Formula 1] wherein s is selected from 0 to 3; The pharma- ceutically acceptable salt is selected from the group consisting of trometamol salt, phosphate salt, citrate salt, oxalate salt, maleate salt, L-tartrate salt, N,N,L-arginine salt, and meglumine salt, preferably trometamol salt, phosphate salt, oxalate salt, maleate salt, p-toluenesulfonate salt, N,L-arginine salt, and meglumine salt, and more preferably trometamol salt and meglumine salt.
2. 2. The pharma- ceutically acceptable salt according to claim 1, wherein the chemical molar ratio of the compound to an acid or base molecule is from 1:2 to 2:1, preferably from 1:2 to 1:1 or from 1:1 to 2:1, preferably from 1:2, 1:1, or 2:
1.
3. 3. A method for preparing a pharma- ceutically acceptable salt according to claim 1 or 2, comprising forming a salt of the compound of formula (I) with an acid or a base.
4. 4. The method according to claim 3, wherein the solvent used in the salt-forming reaction is at least one selected from butanone, methanol, ethanol, tetrahydrofuran, ethyl acetate, isopropanol, acetonitrile, and methyl tert-butyl ether.
5. A pharmaceutical composition comprising the pharma- ceutically acceptable salt of claim 1 and, optionally, a pharma- ceutically acceptable excipient.
6. 13. Use of a pharma- ceutically acceptable salt according to claim 1 in the preparation of a medicament for the prevention and / or treatment of a metabolic disease, preferably said metabolic disease being diabetes, obesity, or non-alcoholic fatty liver disease.
7. A compound of formula (II). [chemical 2] wherein n is selected from 0 to 12.
8. 8. The compound of claim 7, wherein n is selected from 0 to 8, preferably selected from 0 to 5, preferably selected from 0 to 3, preferably n is selected from 0, ½, ⅔, 1, 2, 2.7, and 3.
9. 9. The compound of claim 7 or 8, wherein the compound of formula (II) has the following structure: [C3]
10. Crystalline form A of the compound of formula (II-1), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 11.1426±0.2000°, 14.4804±0.2000°, and 21.4921±0.2000°.
11. 11. The crystalline form A of claim 10, wherein the X-ray powder diffraction pattern of the crystalline form A has characteristic diffraction peaks at the following 2θ angles: 11.1426±0.2000°, 14.4804±0.2000°, 17.7642±0.2000°, 19.6235±0.2000°, and 21.4921±0.2000°.
12. 12. The crystalline form A of claim 11, wherein the X-ray powder diffraction pattern of the crystalline form A has characteristic diffraction peaks at the following 2θ angles: 11.1426±0.2000°, 14.4804±0.2000°, 17.0921±0.2000°, 17.7642±0.2000°, 19.6235±0.2000°, 20.4359±0.2000°, 21.4921±0.2000°, and 22.8874±0.2000°.
13. 13. The crystalline form A of claim 12, wherein the X-ray powder diffraction pattern of the crystalline form A has characteristic diffraction peaks at the following 2θ angles: 5.6759°, 10.2572°, 11.1426°, 14.4804°, 16.2701°, 17.0921°, 17.7642°, 19.6235°, 20.4359°, 20.9310°, 21.4921°, 22.8874°, 25.1971°, 26.5995°, 27.9955°, 28.6836°, 29.4212°, and 30.9896°.
14. 14. The crystalline form A of claim 13, wherein the XRPD pattern of the crystalline form A is essentially as shown in FIG.
15. The crystalline form A according to any one of claims 10 to 14, wherein the differential scanning calorimetry curve of the crystalline form A has endothermic peak values at 76.0±3.0°C and 130.3±3.0°C, respectively.
16. 16. The crystalline form A of claim 15, wherein the DSC thermogram of the crystalline form A is essentially as shown in FIG.
17. The crystalline form A according to any one of claims 10 to 14, wherein the thermogravimetric analysis curve of the crystalline form A has a weight loss of 2.43% at 150.0±3.0°C.
18. 18. The crystalline form A of claim 17, wherein the TGA spectrum of the crystalline form A is essentially as shown in FIG.
19. Crystalline form E of the compound of formula (II), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 18.8216±0.2000°, 20.0568±0.2000°, and 25.1936±0.2000°.
20. 20. The crystalline form E of claim 19, wherein the X-ray powder diffraction pattern of the crystalline form E has characteristic diffraction peaks at the following 2θ angles: 10.8415±0.2000°, 13.3963±0.2000°, 18.8216±0.2000°, 20.0568±0.2000°, and 25.1936±0.2000°.
21. 21. The crystalline form E of claim 20, wherein the X-ray powder diffraction pattern of the crystalline form E has characteristic diffraction peaks at the following 2θ angles: 10.3742±0.2000°, 10.8415±0.2000°, 13.3963±0.2000°, 16.1259±0.2000°, 18.8216±0.2000°, 20.0568±0.2000°, 20.7958±0.2000°, and 25.1936±0.2000°.
22. The X-ray powder diffraction pattern of the crystalline form E has the following 2θ angles: 5.3759°, 10.3742°, 10.8415°, 11.5008°, 13.3963°, 15.7418°, 16.1259°, 16.6392°, 17.2881°, 18.8216°, 19.2577°, 20.0568°, 20.7958°, 21.4850°, 22.1639°, 23.2871°, 24.2871°, 25.2871°, 26.2871°, 27.2871°, 28.2871°, 29.2871°, 30.2871°, 31.2871°, 32.2871°, 33.2871°, 34.2871°, 35.2871°, 36.2871°, 37.2871°, 38.2871°, 39.2871°, 40.2871°, 41.2871°, 42.2871°, 43.2871°, 44.2871°, 45.2871°, 46.2871°, 47.2871°, 48.2871°, 49.2871°, 50.2871°, 51.2871°, 52.2871°, 53.2871°, 54.2871°, 55.2871°, 56.2871°, 22. The crystalline form E of claim 21, having characteristic diffraction peaks at: 24.0777°, 24.1467°, 24.6828°, 25.1936°, 25.5960°, 26.2392°, 26.7365°, 27.1146°, 27.8176°, 28.5679°, 29.6443°, 30.8753°, 33.0123°, 33.8173°, and 36.5754°.
23. 23. The crystalline form E of claim 22, wherein the XRPD pattern of said crystalline form E is substantially as shown in FIG.
24. 24. The crystalline form E of any one of claims 19 to 23, wherein the differential scanning calorimetry curve of the crystalline form E has endothermic peak values at 91.0±3.0°C and 149.9±3.0°C, respectively.
25. 25. The crystalline form E of claim 24, wherein the DSC thermogram of said crystalline form E is essentially as shown in FIG.
26. The crystalline form E according to any one of claims 19 to 23, wherein the thermogravimetric analysis curve of the crystalline form E has a weight loss of 6.37% at 150.0±3.0°C.
27. 27. The crystalline form E of claim 26, wherein the TGA spectrum of the crystalline form E is essentially as shown in FIG.
28. Crystalline form J of the compound of formula (III), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 6.763±0.200°, 13.619±0.200°, and 18.128±0.200°. [C4] wherein i is selected from 0 to 2.
29. 30. The crystalline form J of claim 28, wherein the X-ray powder diffraction pattern of the crystalline form J has characteristic diffraction peaks at the following 2θ angles: 6.763±0.200°, 13.619±0.200°, 15.848±0.200°, 18.128±0.200°, and 24.643±0.200°.
30. 30. The crystalline form J of claim 29, wherein the X-ray powder diffraction pattern of the crystalline form J has characteristic diffraction peaks at the following 2θ angles: 6.763±0.200°, 13.619±0.200°, 15.848±0.200°, 18.128±0.200°, 19.438±0.200°, 21.422±0.200°, 22.621±0.200°, and 24.643±0.200°.
31. The X-ray powder diffraction pattern of the crystalline form J has the following 2θ angles: 6.763°, 9.065°, 9.535°, 11.902°, 12.066°, 12.874°, 13.619°, 14.169°, 14.918°, 15.848°, 16.105°, 16.573°, 17.620°, 18.128°, 18.510°, 18.826°, 19.107°, 19.438°, 20.538°, 21.191°, 21.
31. The crystalline form J of claim 30, having characteristic diffraction peaks at 422°, 21.794°, 22.416°, 22.621°, 22.806°, 23.376°, 23.609°, 24.643°, 25.149°, 25.650°, 27.329°, 28.990°, 29.368°, 29.916°, 30.162°, 31.416°, 33.040°, 33.684°, 35.327°, and 37.570°.
32. 32. The crystalline form J of claim 31 , wherein the XRPD pattern of the crystalline form J is essentially as shown in FIG. 14 .
33. A compound of formula (IV). [C5] (wherein m is selected from 0 to 2).
34. Crystalline form K of the compound of formula (IV-I), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 16.860±0.200°, 18.189±0.200°, and 20.709±0.200°. [C6]
35. 35. The crystalline form K of claim 34, wherein the X-ray powder diffraction pattern of the crystalline form K has characteristic diffraction peaks at the following 2θ angles: 9.972±0.200°, 16.860±0.200°, 18.189±0.200°, 20.709±0.200°, and 23.950±0.200°.
36. 36. The crystalline form K of claim 35, wherein the X-ray powder diffraction pattern of the crystalline form K has characteristic diffraction peaks at the following 2θ angles: 4.581±0.200°, 9.972±0.200°, 10.392±0.200°, 16.860±0.200°, 18.189±0.200°, 20.709±0.200°, 23.950±0.200°, and 26.841±0.200°.
37. 37. The crystalline form K of claim 36, wherein the X-ray powder diffraction pattern of the crystalline form K has characteristic diffraction peaks at the following 2θ angles: 4.581°, 6.439°, 9.972°, 10.232°, 10.392°, 13.328°, 14.053°, 14.696°, 16.860°, 18.189°, 20.709°, 22.766°, 23.950°, 25.785°, and 26.841°.
38. 38. The crystalline form K of claim 37, wherein the XRPD pattern of the crystalline form K is essentially as shown in Figure 15.
39. Crystalline form L of the compound of formula (IV), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 18.726±0.200°, 21.044±0.200°, and 24.648±0.200°.
40. 40. The crystalline form L of claim 39, wherein the X-ray powder diffraction pattern of the crystalline form L has characteristic diffraction peaks at the following 2θ angles: 6.494±0.200°, 18.726±0.200°, 19.547±0.200°, 21.044±0.200°, and 24.648±0.200°.
41. 41. The crystalline form L of claim 40, wherein the X-ray powder diffraction pattern of the crystalline form L has characteristic diffraction peaks at the following 2θ angles: 6.494±0.200°, 15.366±0.200°, 17.885±0.200°, 18.726±0.200°, 19.547±0.200°, 21.044±0.200°, 24.648±0.200°, and 27.453±0.200°.
42. 41. The crystalline form L of claim 40, wherein the X-ray powder diffraction pattern of the crystalline form L has characteristic diffraction peaks at the following 2θ angles: 5.797°, 6.494°, 7.655°, 10.474°, 13.036°, 13.388°, 15.366°, 16.235°, 17.885°, 18.726°, 19.547°, 21.044°, 24.368°, 24.648°, and 27.453°.
43. 43. The crystalline form L of claim 42, wherein the XRPD pattern of said crystalline form L is essentially as shown in FIG.
16.
44. A compound of formula (V). [C7] (wherein o is selected from 0 to 2).
45. Crystalline form M of the compound of formula (V), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 5.682±0.200°, 11.389±0.200°, and 17.202±0.200°.
46. 46. The crystalline form M of claim 45, wherein the X-ray powder diffraction pattern of the crystalline form M has characteristic diffraction peaks at the following 2θ angles: 5.682±0.200°, 11.389±0.200°, 16.009±0.200°, 17.202±0.200°, and 29.418±0.200°.
47. 47. The crystalline form M of claim 46, wherein the X-ray powder diffraction pattern of the crystalline form M has characteristic diffraction peaks at the following 2θ angles: 5.682±0.200°, 11.389±0.200°, 16.009±0.200°, 17.202±0.200°, 17.854±0.200°, 24.147±0.200°, 25.302±0.200°, and 29.418±0.200°.
48. 48. The crystalline form M of claim 47, wherein the X-ray powder diffraction pattern of the crystalline form M has characteristic diffraction peaks at the following 2θ angles: 5.682°, 10.619°, 11.389°, 12.280°, 12.637°, 14.434°, 15.764°, 16.009°, 17.202°, 17.854°, 18.783°, 19.352°, 20.673°, 21.044°, 21.729°, 22.632°, 23.341°, 24.147°, 25.302°, 26.982°, 28.950°, 29.418°, 30.123°, and 33.086°.
49. 49. The crystalline form M of claim 48, wherein the XRPD pattern of said crystalline form M is essentially as shown in FIG.
50. A compound of formula (VI). [C8]
51. Crystalline form N of the compound of formula (VI), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 11.439±0.200°, 18.363±0.200°, and 28.859±0.200°.
52. 52. The crystalline form N of claim 51, wherein the X-ray powder diffraction pattern of the crystalline form N has characteristic diffraction peaks at the following 2θ angles: 11.439±0.200°, 18.363±0.200°, 20.062±0.200°, 22.657±0.200°, and 28.859±0.200°.
53. 53. The crystalline form N of claim 52, wherein the X-ray powder diffraction pattern of the crystalline form N has characteristic diffraction peaks at the following 2θ angles: 8.581±0.200°, 11.439±0.200°, 18.363±0.200°, 20.062±0.200°, 22.657±0.200°, 23.664±0.200°, 25.356±0.200°, and 28.859±0.200°.
54. The X-ray powder diffraction pattern of the crystalline form N has the following 2θ angles: 5.697°, 8.581°, 8.801°, 11.439°, 12.051°, 12.568°, 13.226°, 14.357°, 14.846°, 15.655°, 16.120°, 17.223°, 17.880°, 18.363°, 18.914°, 19.236°, 20.062°, 20.397°, 21.454°, 22.657° 54. The crystalline form N of claim 53, having characteristic diffraction peaks at 22.991°, 23.664°, 24.391°, 24.844°, 25.356°, 26.003°, 26.573°, 26.956°, 27.309°, 28.283°, 28.859°, 29.089°, 29.935°, 31.553°, 31.847°, 32.174°, 32.715°, 34.782°, and 38.569°.
55. 55. The crystalline form N of claim 54, wherein the XRPD pattern of said crystalline form N is essentially as shown in FIG.
18.
56. A compound of formula (VII). [C9] (wherein p is selected from 0 to 3).
57. Crystalline form O of the compound of formula (VII), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 9.485±0.200°, 11.273±0.200°, and 17.536±0.200°.
58. 58. The crystalline form O of claim 57, wherein the X-ray powder diffraction pattern of the crystalline form O has characteristic diffraction peaks at the following 2θ angles: 9.485±0.200°, 11.273±0.200°, 12.495±0.200°, 17.536±0.200°, and 18.874±0.200°.
59. 59. The crystalline form O of claim 58, wherein the X-ray powder diffraction pattern of the crystalline form O has characteristic diffraction peaks at the following 2θ angles: 9.485±0.200°, 11.273±0.200°, 12.495±0.200°, 15.005±0.200°, 17.536±0.200°, 18.874±0.200°, 19.568±0.200°, and 20.291±0.200°.
60. 60. The crystalline form O of claim 59, wherein the X-ray powder diffraction pattern of the crystalline form O has characteristic diffraction peaks at the following 2θ angles: 4.859°, 7.487°, 9.485°, 10.000°, 11.273°, 12.495°, 12.842°, 14.649°, 15.005°, 16.766°, 17.536°, 18.874°, 19.568°, 20.082°, 20.291°, 21.189°, 22.679°, 23.508°, 25.140°, 25.788°, 28.081°, 29.067°, 29.739°, 31.639°, and 35.581°.
61. 61. The crystalline form O of claim 60, wherein the XRPD pattern of the crystalline form O is essentially as shown in FIG.
62. Crystalline form P of the compound of formula (VII), characterized in that the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 12.481±0.200°, 14.965±0.200°, and 17.480±0.200°.
63. 63. The crystalline form P of claim 62, wherein the X-ray powder diffraction pattern of crystalline form P has characteristic diffraction peaks at the following 2θ angles: 9.998±0.200°, 12.481±0.200°, 14.965±0.200°, 17.480±0.200°, and 19.969±0.200°.
64. 64. The crystalline form P of claim 63, wherein the X-ray powder diffraction pattern of crystalline form P has characteristic diffraction peaks at the following 2θ angles: 5.007°, 7.512°, 9.604°, 9.998°, 12.481°, 14.965°, 17.480°, 18.908°, 19.969°, 20.933°, 25.629°, 27.587°, and 35.375°.
65. 65. The crystalline form P of claim 64, wherein the XRPD pattern of the crystalline form P is essentially as shown in FIG.
20.
66. A compound of formula (VIII). [C10]
67. Crystalline form Q of the compound of formula (VIII), characterized in that its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 6.123±0.200°, 9.130±0.200°, and 12.123±0.200°.
68. 68. The crystalline form Q of claim 67, wherein the X-ray powder diffraction pattern of the crystalline form Q has characteristic diffraction peaks at the following 2θ angles: 6.123±0.200°, 9.130±0.200°, 12.123±0.200°, 20.095±0.200°, and 22.942±0.200°.
69. 69. The crystalline form Q of claim 68, wherein the X-ray powder diffraction pattern of the crystalline form Q has characteristic diffraction peaks at the following 2θ angles: 6.123±0.200°, 9.130±0.200°, 12.123±0.200°, 15.071±0.200°, 18.151±0.200°, 20.095±0.200°, 22.045±0.200°, and 22.942±0.200°.
70. The X-ray powder diffraction pattern of the crystalline form Q has the following 2θ angles: 6.123°, 7.677°, 9.130°, 10.013°, 11.598°, 12.123°, 14.770°, 15.071°, 15.986°, 16.493°, 16.692°, 17.365°, 18.151°, 18.915°, 20.095°, 20.569°, 21.147°, 22.
70. The crystalline form Q of claim 69, having characteristic diffraction peaks at: 22.045°, 22.942°, 24.106°, 24.617°, 26.108°, 27.014°, 27.822°, 28.433°, 29.464°, 30.256°, 30.863°, 31.820°, 33.446°, 34.822°, 36.389°, 37.646°, and 37.803°.
71. 71. The crystalline form Q of claim 70, wherein the XRPD pattern of the crystalline form Q is essentially as shown in FIG.
21.
72. Use of a compound according to any one of claims 7 to 9, 33, 44, 50, 56 or 66, or crystalline form A according to any one of claims 10 to 18, or crystalline form E according to any one of claims 19 to 27, or crystalline form J according to any one of claims 28 to 32, or crystalline form K according to any one of claims 34 to 38, or crystalline form L according to any one of claims 39 to 43, or crystalline form M according to any one of claims 45 to 49, or crystalline form N according to any one of claims 51 to 55, or crystalline form O according to any one of claims 57 to 61, or crystalline form P according to any one of claims 62 to 65, or crystalline form Q according to any one of claims 67 to 71, in the preparation of a medicament for treating a metabolic disease.
73. A compound of formula (III). [C11] wherein i is selected from 0 to 2.
Citation Information
Patent Citations
Five-membered heteroaromatic imidazole compounds and their uses
JP7359974B2
GLP-1r agonists and uses thereof
WO2020103815A1
GLP-1r agonists and uses thereof
WO2020207474A1
Small molecule GLP-1 receptor modulator
WO2021018023A1
Five-membered ring derivative and medical use thereof
WO2022135572A1
